Generated by All in One SEO Pro v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Costello Medical

## Sitemaps

- [XML Sitemap](https://www.costellomedical.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [ISPOR APAC 2022 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-apac-2022-report/)
- [ISPOR Europe 2022 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-eu-2022-report/)
- [PALYs and PALE: Measuring Productivity Losses in HTA](https://www.costellomedical.com/news-and-views/articles-publications/palys-and-pale-measuring-productivity-losses-in-hta/)
- [Costello Medical is Now Employee-Owned](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-is-now-employee-owned/) - We’re proud to share an important milestone in Costello Medical’s journey: our transition to employee ownership. Our company is now owned by an Employee Ownership Trust (EOT), a structure designed to secure our long-term future, protect the culture we’ve built, and ensure that Costello Medical continues to deliver exceptional work to our clients for generations to come.
- [Whether, When and How to EU JSC](https://www.costellomedical.com/news-and-views/articles-publications/whether-when-and-how-to-eu-jsc/)
- [MedComms in the New Digital Era: Insights from SXSW London](https://www.costellomedical.com/news-and-views/articles-publications/medcomms-in-the-new-digital-era-insights-from-sxsw-london/)
- [Changes to the UK Rare Diseases Landscape in 2026](https://www.costellomedical.com/news-and-views/articles-publications/changes-to-the-uk-rare-diseases-landscape-in-2026/) - Test test
- [R for Health Technology Assessment 2026: Key HEOR Insights](https://www.costellomedical.com/news-and-views/articles-publications/r-for-health-technology-assessment-2026-key-heor-insights/)
- [The Role of Digital Design in Medical Communications](https://www.costellomedical.com/news-and-views/articles-publications/digital-design-in-medical-communications/)
- [Beyond the Static: Motion Design Brings Healthcare to Life](https://www.costellomedical.com/news-and-views/articles-publications/beyond-the-static-motion-design-brings-healthcare-to-life/)
- [Graphic Design in MedComms: Decoding Complex Information](https://www.costellomedical.com/news-and-views/articles-publications/graphic-design-in-medcomms-decoding-complex-information/)
- [The Commercial Value of Patient Engagement](https://www.costellomedical.com/news-and-views/articles-publications/the-commercial-value-of-patient-engagement/)
- [Catalyst for Change or Status Quo? Reflections on TSD 26 on Expert Elicitation](https://www.costellomedical.com/news-and-views/articles-publications/catalyst-for-change-or-status-quo-reflections-on-tsd-26-on-expert-elicitation/)
- [Patient Engagement in HTA](https://www.costellomedical.com/news-and-views/articles-publications/patient-engagement-in-hta/)
- [Open AI ≠ Open Writing: How Transparent is Current Use and Disclosure of Artificial Intelligence in Publications?](https://www.costellomedical.com/news-and-views/articles-publications/open-ai-≠-open-writing-how-transparent-is-current-use-and-disclosure-of-artificial-intelligence-in-publications/)
- [How Much Time Does Artificial Intelligence Really Save in Evidence Synthesis? A Systematic Literature Review](https://www.costellomedical.com/news-and-views/articles-publications/how-much-time-does-artificial-intelligence-really-save-in-evidence-synthesis-a-systematic-literature-review-2/)
- [Harnessing Large-Language Models for Efficient Data Extraction in Systematic Reviews: The Role of Prompt Engineering](https://www.costellomedical.com/news-and-views/articles-publications/large-language-models-for-data-extraction-systematic-reviews/)
- [Performance and Practicality of a Randomized Clinical Trial Classifier in Systematic Literature Reviews vs a Traditional Approach](https://www.costellomedical.com/news-and-views/articles-publications/performance-practicality-rct-classifier-systematic-literature-reviews-vs-traditional-approach/)
- [Harnessing AI for Quality Assessment in Economic Literature Reviews: Development and Testing of Drummond Checklist Prompts](https://www.costellomedical.com/news-and-views/articles-publications/ai-quality-assessment-economic-literature-reviews/)
- [How Much Time Does Artificial Intelligence Really Save in Evidence Synthesis? A Systematic Literature Review](https://www.costellomedical.com/news-and-views/articles-publications/how-much-time-does-artificial-intelligence-really-save-in-evidence-synthesis-a-systematic-literature-review/)
- [Harnessing Generative Artificial Intelligence for Global Value Dossier Development](https://www.costellomedical.com/news-and-views/articles-publications/harnessing-generative-artificial-intelligence-for-global-value-dossier-development/)
- [An Early Start: Preliminary ITC Assessments Informing Evidence Generation Planning for JCA](https://www.costellomedical.com/news-and-views/articles-publications/an-early-start-preliminary-itc-assessments-informing-evidence-generation-planning-for-jca/)
- [No Strong Preference? Acceptance of the Quantitative Incorporation of Patient Preference in Economic Modelling in Past NICE Technology Appraisals](https://www.costellomedical.com/news-and-views/articles-publications/35010/)
- [Understanding the Impact of Equality and Equity Considerations on NICE Highly Specialised Technology (HST) Decision-Making](https://www.costellomedical.com/news-and-views/articles-publications/understanding-the-impact-of-equality-and-equity-considerations-on-nice-highly-specialised-technology-hst-decision-making/)
- [Unlocking Value Early: Insights into NICE’s Early Value Assessments and Evidence Generation Plans for Medical Technologies](https://www.costellomedical.com/news-and-views/articles-publications/unlocking-value-early-insights-into-nices-early-value-assessments-and-evidence-generation-plans-for-medical-technologies/)
- [Accounting for the Additional Uncertainty Following Rank Preserving Structural Failure Time Model (RPSFTM) Crossover Adjustment in Survival Analysis: A ‘SAGE’ Approach](https://www.costellomedical.com/news-and-views/articles-publications/accounting-for-the-additional-uncertainty-following-rank-preserving-structural-failure-time-model-rpsftm-crossover-adjustment-in-survival-analysis-a-sage-approach/)
- [Expert Consensus on a Definition for Children with Medical Complexity in England: A Modified Delphi Panel](https://www.costellomedical.com/news-and-views/articles-publications/expert-consensus-on-a-definition-for-children-with-medical-complexity-in-england-a-modified-delphi-panel/)
- [Excel Front-End, R Back-End: A Gateway To Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA](https://www.costellomedical.com/news-and-views/articles-publications/excel-front-end-r-back-end-a-gateway-to-faster-individual-patient-simulations-and-probabilistic-sensitivity-analyses-in-cost-effectiveness-models-for-hta/)
- [Does Modelling Adherence Matter? Insights from Prior NICE Appraisals](https://www.costellomedical.com/news-and-views/articles-publications/does-modelling-adherence-matter-insights-from-prior-nice-appraisals/)
- [Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?](https://www.costellomedical.com/news-and-views/articles-publications/deep-brain-stimulation-a-cost-saving-treatment-option-for-extreme-treatment-refractory-obsessive-compulsive-disorder-in-the-uk/)
- [Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis](https://www.costellomedical.com/news-and-views/articles-publications/comparative-analysis-of-pan-european-severity-assessment-methods-and-their-uncertainty-in-cost-effectiveness-analysis-2/)
- [Why TSD26 Matters: How Accurate was Clinical Expert Opinion in Estimating Long-Term Outcomes?](https://www.costellomedical.com/news-and-views/articles-publications/why-tsd26-matters-how-accurate-was-clinical-expert-opinion-in-estimating-long-term-outcomes/)
- [Trends and Tensions in NICE Severity Modifiers: Analysing the Acceptance and Critique of Manufacturer Severity Modifier Proposals in Recent Appraisals](https://www.costellomedical.com/news-and-views/articles-publications/trends-and-tensions-in-nice-severity-modifiers-analysing-the-acceptance-and-critique-of-manufacturer-severity-modifier-proposals-in-recent-appraisals/)
- [Determinants of Willingness to Pay Thresholds in NICE Oncology Appraisals](https://www.costellomedical.com/news-and-views/articles-publications/determinants-of-willingness-to-pay-thresholds-in-nice-oncology-appraisals/)
- [Value Assessment Frameworks Fit for the Digital Age](https://www.costellomedical.com/news-and-views/articles-publications/value-assessment-frameworks-fit-for-the-digital-age/)
- [ISPOR Europe 2023 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-europe-2023-report/)
- [Industry Spotlight: Health Economic Modelling in MedTech](https://www.costellomedical.com/news-and-views/articles-publications/economic-modelling-medtech/)
- [An Early Start: Preliminary Indirect Treatment Comparison Assessments Informing Evidence-Generation Planning for Joint Clinical Assessment](https://www.costellomedical.com/news-and-views/articles-publications/an-early-start-preliminary-indirect-treatment-comparison-assessments-informing-evidence-generation-planning-for-joint-clinical-assessment/)
- [Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe](https://www.costellomedical.com/news-and-views/articles-publications/mind-the-gap-exploring-variation-in-guidelines-for-indirect-treatment-comparison-itc-across-europe/)
- [Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis](https://www.costellomedical.com/news-and-views/articles-publications/comparative-analysis-of-pan-european-severity-assessment-methods-and-their-uncertainty-in-cost-effectiveness-analysis/)
- [How the 10 Year Health Plan Could Transform Real-World Evidence in the UK](https://www.costellomedical.com/news-and-views/articles-publications/how-the-10-year-health-plan-could-transform-real-world-evidence-in-the-uk/)
- [The Role of Patients in Scientific Congresses: Benefits, Challenges and Future Opportunities](https://www.costellomedical.com/news-and-views/articles-publications/patients-in-scientific-congresses/)
- [Diverse Insights: Exploring Multistakeholder Engagement During Delphi Panels](https://www.costellomedical.com/news-and-views/articles-publications/diverse-insights-delphi-panels/)
- [Navigating the Data Wilderness: Best Practices in Real-World Data Source Landscaping](https://www.costellomedical.com/news-and-views/articles-publications/navigating-the-data-wilderness-best-practices-in-real-world-data-source-landscaping/)
- [What's this Button for? Digital Health is Being Held to a Higher Standard](https://www.costellomedical.com/news-and-views/articles-publications/digital-health/)
- [To Incentivise a “Whole Health” Approach, We Need to Fix the “Wrong Pocket Problem”](https://www.costellomedical.com/news-and-views/articles-publications/incentivising-whole-health-approach/)
- [Overcoming Hesitancy to Include Real-World Evidence (RWE) in Reimbursement Submissions](https://www.costellomedical.com/news-and-views/articles-publications/real-world-evidence-in-reimbursement-submissions/)
- [IRA and US Drug Price Negotiations](https://www.costellomedical.com/news-and-views/articles-publications/ira-and-us-drug-price-negotiations/)
- [Ignorance is not Bliss: The Value of Diagnostics in the Absence of Optimal Therapies](https://www.costellomedical.com/news-and-views/articles-publications/value-of-diagnostics/)
- [From Promise to Practice: The Evolving Role of GenAI in HEOR](https://www.costellomedical.com/news-and-views/articles-publications/the-evolving-role-of-genai-in-heor/)
- [Advancing Statistical Methods: Innovations at ISPOR 2024](https://www.costellomedical.com/news-and-views/articles-publications/advancing-statistical-methods-innovations-at-ispor-2024/)
- [ISPOR International Report 2024](https://www.costellomedical.com/news-and-views/articles-publications/ispor-international-report-2024/)
- [Crossing Borders, Bridging Gaps: Can Data Transportability Connect Patients to Therapies Faster?](https://www.costellomedical.com/news-and-views/articles-publications/crossing-borders-bridging-gaps-can-data-transportability-connect-patients-to-therapies-faster/)
- [From Trendy to Timeless: Sustaining Patient Access to Rare Disease Therapies in a Shifting Landscape](https://www.costellomedical.com/news-and-views/articles-publications/patient-access-rare-disease-therapies/)
- [The Bigger Picture: Considering Broader Value Drivers and Perspectives in HEOR](https://www.costellomedical.com/news-and-views/articles-publications/broader-value-drivers-and-perspectives-in-heor/)
- [How Can We Navigate Uncertainty in Comparative Effectiveness Analyses? - Advances in Statistical Techniques for HTA](https://www.costellomedical.com/news-and-views/articles-publications/advances-in-statistical-techniques/)
- [RWE and HTA for Diagnostics and Devices](https://www.costellomedical.com/news-and-views/articles-publications/rwe-medical-devices-diagnostics/)
- [Will JCA Set the Tempo For Increased Global Harmonisation in the Access Landscape?](https://www.costellomedical.com/news-and-views/articles-publications/jca-increased-global-harmonisation/)
- [The Home Stretch: Is Europe Any More Ready for the HTAR One Year On?](https://www.costellomedical.com/news-and-views/articles-publications/europe-htar-ready/)
- [Trust Me I’m a (Ph)Doctor: Ensuring Integrity and Reliability in AI-Augmented HEOR Work](https://www.costellomedical.com/news-and-views/articles-publications/ai-augmented-heor/)
- [ISPOR Europe 2024 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-europe-2024-report/)
- [US Healthcare Policy in Flux – What We Know & Don’t Know](https://www.costellomedical.com/news-and-views/articles-publications/us-healthcare-policy-in-flux/)
- [HEOR for All: Methodological Advancements to Promote Inclusivity and Equity in Healthcare Decision-Making](https://www.costellomedical.com/news-and-views/articles-publications/heor-methodological-advancements-to-promote-inclusivity-and-equity-in-healthcare-decision-making/)
- [Like It or Not, It’s Here to Stay: AI Applications in HEOR](https://www.costellomedical.com/news-and-views/articles-publications/like-it-or-not-its-here-to-stay-ai-applications-in-heor/)
- [Revolutionising Rare Disease Data Generation](https://www.costellomedical.com/news-and-views/articles-publications/rare-disease-data-generation/)
- [Literature Reviews – The Promised ‘Low-Hanging Fruit’ Application of AI in HEOR?](https://www.costellomedical.com/news-and-views/articles-publications/ai-in-heor-literature-reviews/)
- [ISPOR Barcelona 2018 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-barcelona-report-2018/)
- [ISPOR US 2019 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-usa-report-2019/)
- [ISMPP Asia-Pacific 2019 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-asia-pacific-2019-report/)
- [ISPOR Copenhagen 2019 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-copenhagen-report-2019/)
- [ISMPP EU 2020 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-report-2020/)
- [ISPOR Annual Meeting 2020 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-annual-meeting-report-2020/)
- [ISMPP EU 2021 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-report-2021/)
- [ISPOR US 2021 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-us-report-2021/)
- [AMCP 2022 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-amcp-2022-report/)
- [ISPOR US 2022 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-us-2022-report/)
- [ISMPP EU 2022 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-report-2022/)
- [ISMPP EU 2023 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-report-2023/)
- [AMCP 2023 Report](https://www.costellomedical.com/news-and-views/articles-publications/amcp-2023-report/)
- [ISPOR US 2023 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-spor-us-2023-report/)
- [ISMPP EU 2024 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-report-2024/)
- [ISMPP EU 2025 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ismpp-eu-2025-report/)
- [ISPOR International 2025 Report](https://www.costellomedical.com/news-and-views/articles-publications/costello-medical-ispor-international-2025-report/)
- [ABHI UK HealthTech Conference 2023 Round-up](https://www.costellomedical.com/news-and-views/articles-publications/abhi-uk-healthtech-conference-round-up/)
- [In Defence of the Targeted Literature Review](https://www.costellomedical.com/news-and-views/articles-publications/targeted-literature-review/)
- [Better Together: The Impact of Joint Clinical Assessments on Systematic Literature Reviews](https://www.costellomedical.com/news-and-views/articles-publications/better-together-the-impact-of-joint-clinical-assessments-on-systematic-literature-reviews/)
- [The Critical Role of the Global Value Dossier in EU Joint Clinical Assessment](https://www.costellomedical.com/news-and-views/articles-publications/the-critical-role-of-the-global-value-dossier-in-eu-joint-clinical-assessment/)
- [Navigating the Challenges of Joint Clinical Assessment for Advanced Therapy Medicinal Products](https://www.costellomedical.com/news-and-views/articles-publications/navigating-the-challenges-of-joint-clinical-assessment-for-advanced-therapy-medicinal-products/)
- [Review of Guidelines for Direct and Indirect Comparisons for JCA: Familiar Territory Through a Cautious Lens](https://www.costellomedical.com/news-and-views/articles-publications/review-of-guidelines-for-direct-and-indirect-comparisons-for-jca/)
- [The Joint Clinical Assessment Dossier: A Fresh Approach or Business as Usual?](https://www.costellomedical.com/news-and-views/articles-publications/the-joint-clinical-assessment-dossier-a-fresh-approach-or-business-as-usual/)
- [Ready for EU Joint Clinical Assessment (JCA): Key Reflections from 2024 & Important Unknowns](https://www.costellomedical.com/news-and-views/articles-publications/jca-2024-key-reflections/)
- [Innovating Literature Reviews with AI: Our Approach](https://www.costellomedical.com/news-and-views/articles-publications/innovating-literature-reviews-with-ai-our-approach/)
- [Incorporation of Minimally Important Differences in Network Meta-Analysis](https://www.costellomedical.com/news-and-views/articles-publications/incorporation-of-minimally-important-differences-in-network-meta-analysis/)
- [Artificial Intelligence in Network Meta-Analysis for HTA](https://www.costellomedical.com/news-and-views/articles-publications/artificial-intelligence-in-network-meta-analysis-for-hta/)
- [Revisions to NICE’s Highly Specialised Technologies Routing Criteria: What Will These Mean for Future Ultra-Orphan Technologies?](https://www.costellomedical.com/news-and-views/articles-publications/revisions-to-nices-highly-specialised-technologies-routing-criteria/)
- [Updates to NICE Methods and Processes](https://www.costellomedical.com/news-and-views/articles-publications/updates-to-nice-methods-and-processes/)
- [Value Dossiers for MedTech: Back to the Drawing Board?](https://www.costellomedical.com/news-and-views/articles-publications/value-dossiers-for-medtech-back-to-the-drawing-board/)
- [Navigating Diverse Educational Needs in MedTech](https://www.costellomedical.com/news-and-views/articles-publications/navigating-diverse-educational-needs-in-medtech/)
- [Opinions on the NICE HealthTech Programme Consultation](https://www.costellomedical.com/news-and-views/articles-publications/opinions-on-the-nice-healthtech-programme-consultation/)
- [Public Engagement on Building an Integrated, Rules-Based Medical Technology (MedTech) Pathway in England](https://www.costellomedical.com/news-and-views/articles-publications/public-engagement-on-building-an-integrated-rules-based-medical-technology-medtech-pathway-in-england/)
- [Public Consultation on Including Technology Appraisal Guidance in NICE Guidelines: ‘Incorporation’ versus ‘Integration’?](https://www.costellomedical.com/news-and-views/articles-publications/public-consultation-on-including-technology-appraisal-guidance-in-nice-guidelines/)
- [Public Consultation on NICE Integrated Topic Prioritisation and Strategic Principles: What’s Set To Change?](https://www.costellomedical.com/news-and-views/articles-publications/public-consultation-on-nice-integrated-topic-prioritisation-and-strategic-principles-whats-set-to-change/)
- [NICE’s ‘Proportionate Approach to Technology Appraisals (PATT)’: The Story So Far](https://www.costellomedical.com/news-and-views/articles-publications/nices-proportionate-approach-to-technology-appraisals-patt-the-story-so-far/)
- [Health Inequalities: NICE Takes a Step Forward](https://www.costellomedical.com/news-and-views/articles-publications/health-inequalities-nice-takes-a-step-forward/)
- [Unlocking Value: 5 Top Tips for a Winning Value Dossier](https://www.costellomedical.com/news-and-views/articles-publications/unlocking-value-5-top-tips-for-a-winning-value-dossier/)
- [Unlocking AI’s Potential in Value and Access Writing](https://www.costellomedical.com/news-and-views/articles-publications/unlocking-ais-potential-in-value-and-access-writing/)
- [Data Detectives: Overcoming the Challenges of a Rare Disease Evidence Base to Develop a Compelling Value Narrative](https://www.costellomedical.com/news-and-views/articles-publications/data-detectives-overcoming-the-challenges-of-a-rare-disease-evidence-base-to-develop-a-compelling-value-narrative/)
- [Elevating Value Dossiers with Patient-Centric Strategies](https://www.costellomedical.com/news-and-views/articles-publications/patient-centric-value-dossiers/)
- [Analysis of 20 Years of Legislative Trends to Predict Future Investment and Access to Orphan Drugs](https://www.costellomedical.com/news-and-views/articles-publications/orphan-drug-legislation-trends/)
- [Relationships Between ICER Clinical Evidence Ratings and FDA Approval Decisions](https://www.costellomedical.com/news-and-views/articles-publications/icer-evidence-ratings-fda-approvals/)
- [Learnings from State and Federal Drug Pricing Negotiations Across the United States: The Impact of Prescription Drug Affordability Boards](https://www.costellomedical.com/news-and-views/articles-publications/drug-pricing-negotiations-us-pdab-impact/)
- [Characterizing Cardiovascular Disease Patients in US Community Hospitals Using insightsDB](https://www.costellomedical.com/news-and-views/articles-publications/cvd-patients-us-hospitals-insightsdb/)
- [Data Extraction in Literature Reviews Using an Artificial Intelligence Model: Prompt Development and Testing](https://www.costellomedical.com/news-and-views/articles-publications/ai-data-extraction-literature-reviews/)
- [Moving Beyond Partitioned Survival Models in Oncology Submissions: Incorporation of Canada’s Drug Agency Guidance on Model Structure](https://www.costellomedical.com/news-and-views/articles-publications/cda-oncology-model-guidance/)
- [The Impact of RSV Vaccine Rollout in England](https://www.costellomedical.com/news-and-views/articles-publications/the-impact-of-rsv-vaccine-rollout-in-england/)
- [Unquantified Insights: An Assessment of NICE’s Qualitative Research Appendix](https://www.costellomedical.com/news-and-views/articles-publications/unquantified-insights-an-assessment-of-nices-qualitative-research-appendix/)
- [Systematic Literature Reviews: An Exercise in Compromise?](https://www.costellomedical.com/news-and-views/articles-publications/systematic-literature-reviews/)
- [The Dawn of Real-World Evidence Frameworks: Where Does NICE Fit In?](https://www.costellomedical.com/news-and-views/articles-publications/real-world-evidence-frameworks-nice/)
- [AI in Literature Reviews: Maximising Benefits, Reducing Harms](https://www.costellomedical.com/news-and-views/articles-publications/ai-in-literature-reviews/)
- [Shaping Health Policy and Clinical Practice: A Critical Evaluation of Literature Review Methods in the Evidence Base](https://www.costellomedical.com/news-and-views/articles-publications/shaping-health-policy-and-clinical-practice-a-critical-evaluation-of-literature-review-methods-in-the-evidence-base/)
- [How Do Healthcare Professionals Perceive Delphi Panels and Use Study Outcomes?](https://www.costellomedical.com/news-and-views/articles-publications/delphi-panels-study-outcomes/)
- [Beyond Agreement: How Is Non-Consensus Handled in Delphi Panels?](https://www.costellomedical.com/news-and-views/articles-publications/non-consensus-in-delphi-panels/)
- [Policy Reports That Create Impact: Insights From a Roundtable Case Study](https://www.costellomedical.com/news-and-views/articles-publications/policy-reports-that-create-impact/)
- [Speaking Their Language: Healthcare Professionals’ Use of Plain Language Materials with Patients](https://www.costellomedical.com/news-and-views/articles-publications/plain-language-materials-with-patients/)
- [Behind the Numbers: What Publishers Know About Your Article](https://www.costellomedical.com/news-and-views/articles-publications/what-publishers-know-about-your-article/)
- [Trust the Experts? Acceptance of Expert Elicitation in the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) Process](https://www.costellomedical.com/news-and-views/articles-publications/trust-the-experts-acceptance-of-expert-elicitation-in-the-national-institute-for-health-and-care-excellence-nice-single-technology-appraisal-sta-process/)
- [Approaches to the Collection of Utility Values for Rare Diseases](https://www.costellomedical.com/news-and-views/articles-publications/approaches-to-the-collection-of-utility-values-for-rare-diseases/)
- [Approaches to the Collection of Utility Values for Rare Diseases: A Cross-Country Comparison](https://www.costellomedical.com/news-and-views/articles-publications/rare-diseases-utilities/)
- [Probabilistic Cost-Effectiveness Results and Managed Access Agreements: A Review of Therapies Entering the Cancer Drugs Fund in England](https://www.costellomedical.com/news-and-views/articles-publications/therapies-cancer-drug-fund-england/)
- [Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology](https://www.costellomedical.com/news-and-views/articles-publications/adoption-of-piecewise-modelling-a-review-of-nice-health-technology-appraisals-in-oncology/)
- [Adoption of Piecewise Modelling: A Review of NICE Health Technology Appraisals in Oncology](https://www.costellomedical.com/news-and-views/articles-publications/adoption-of-piecewise-modelling-a-review-of-nice-health-technology-appraisals-in-oncology-2/)
- [When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning](https://www.costellomedical.com/news-and-views/articles-publications/when-does-a-treatment-effect-really-stop-exploration-of-different-methods-for-modelling-treatment-waning-2/)
- [What Is the Cost of Increased Flexibility in Reimbursement Decision-Making?](https://www.costellomedical.com/news-and-views/articles-publications/what-is-the-cost-of-increased-flexibility-in-reimbursement-decision-making/)
- [A Distributional Cost-Effectiveness Analysis of Cervical Cancer Screening Strategies in England](https://www.costellomedical.com/news-and-views/articles-publications/a-distributional-cost-effectiveness-analysis-of-cervical-cancer-screening-strategies-in-england/)
- [The NICE Diagnostics Assessment Programme: Does Assessment Lead to Approval?](https://www.costellomedical.com/news-and-views/articles-publications/the-nice-diagnostics-assessment-programme-does-assessment-lead-to-approval/)
- [Acceptance of Cure Assumptions in NICE Oncology Technology Appraisals: Remission Impossible?](https://www.costellomedical.com/news-and-views/articles-publications/acceptance-of-cure-assumptions-in-nice-oncology-technology-appraisals-remission-impossible/)
- [Comparison of Methods to Estimate Total Person-Time at Risk for Synthesis Studies of Incidence Rates in Observational Data](https://www.costellomedical.com/news-and-views/articles-publications/comparison-of-methods-to-estimate-total-person-time-at-risk-for-synthesis-studies-of-incidence-rates-in-observational-data/)
- [Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?](https://www.costellomedical.com/news-and-views/articles-publications/company-led-submissions-to-the-agency-for-care-effectiveness-ace-in-singapore-what-drives-patient-access/)
- [When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning](https://www.costellomedical.com/news-and-views/articles-publications/when-does-a-treatment-effect-really-stop-exploration-of-different-methods-for-modelling-treatment-waning/)
- [What's the Hold Up? Factors Influencing Manuscript Development Time](https://www.costellomedical.com/news-and-views/articles-publications/whats-the-hold-up-factors-influencing-manuscript-development-time/)
- [Risk of All-Cause Mortality in Alcohol-Dependent Individuals: A Systematic Literature Review and Meta-Analysis.](https://www.costellomedical.com/news-and-views/articles-publications/risk-of-all-cause-mortality-in-alcohol-dependent-individuals-a-systematic-literature-review-and-meta-analysis/)
- [Are we there yet? Does Current Practice in Acknowledging Professional Medical Writing Support Meet the Requirements of GPP3?](https://www.costellomedical.com/news-and-views/articles-publications/are-we-there-yet-does-current-practice-in-acknowledging-professional-medical-writing-support-meet-the-requirements-of-gpp3/)
- [Know Your Audience: Avoiding Redundant Abstract Publications](https://www.costellomedical.com/news-and-views/articles-publications/know-your-audience-avoiding-redundant-abstract-publications/)
- [Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques](https://www.costellomedical.com/news-and-views/articles-publications/pharmacological-interventions-for-familial-hypercholesterolaemia-in-children-and-adolescents-an-exploratory-evaluation-using-advanced-hierarchical-network-meta-analysis-techniques/)
- [The Impact of Hepatitis C Virus Outside the Liver: Evidence from Asia](https://www.costellomedical.com/news-and-views/articles-publications/the-impact-of-hepatitis-c-virus-outside-the-liver-evidence-from-asia/)
- [Using Augmented Reality for Congress Posters: Challenges and Considerations](https://www.costellomedical.com/news-and-views/articles-publications/using-augmented-reality-for-congress-posters-challenges-and-considerations/)
- [The Role of Scientific Interns as Medical Publication Professionals](https://www.costellomedical.com/news-and-views/articles-publications/the-role-of-scientific-interns-as-medical-publication-professionals/)
- [The Prevalence and Characteristics of Lay Summaries of Published Journal Articles](https://www.costellomedical.com/news-and-views/articles-publications/the-prevalence-and-characteristics-of-lay-summaries-of-published-journal-articles/)
- [ISMPP European Meeting, London 2017, Report](https://www.costellomedical.com/news-and-views/articles-publications/ismpp-european-meeting-london-2017/)
- [Maximising Research Impact: Is Less More?](https://www.costellomedical.com/news-and-views/articles-publications/maximising-research-impact-is-less-more/)
- [Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels](https://www.costellomedical.com/news-and-views/articles-publications/inequity-in-healthcare-access-in-asian-countries-with-reportedly-high-universal-health-coverage-levels/)
- [Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)?](https://www.costellomedical.com/news-and-views/articles-publications/small-and-medium-sized-enterprises-how-do-they-fare-in-the-uk-medical-technologies-evaluation-programme-mtep/)
- [Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism](https://www.costellomedical.com/news-and-views/articles-publications/cost-effectiveness-of-pet-ct-versus-adrenal-vein-sampling-for-the-diagnosis-of-hypertension-caused-by-primary-aldosteronism/)
- [Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks](https://www.costellomedical.com/news-and-views/articles-publications/value-frameworks-to-set-tongues-wagging-analysis-of-opinions-and-discussions-on-key-value-frameworks/)
- [ISPOR 22nd Annual International Congress, Boston 2017, Report](https://www.costellomedical.com/news-and-views/articles-publications/ispor-22nd-annual-international-congress-boston-2017/)
- [NICE Annual Conference, London 2017, Report](https://www.costellomedical.com/news-and-views/articles-publications/nice-annual-conference-2017/)
- [ISMPP 13th Annual International Meeting, Washington 2017, Report](https://www.costellomedical.com/news-and-views/articles-publications/ismpp-13th-annual-international-meeting-washington-2017/)
- [Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism](https://www.costellomedical.com/news-and-views/articles-publications/cost-effectiveness-of-pet-ct-versus-adrenal-vein-sampling-for-the-diagnosis-of-hypertension-caused-by-primary-aldosteronism-2/)
- [Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels](https://www.costellomedical.com/news-and-views/articles-publications/inequity-in-healthcare-access-in-asian-countries-with-reportedly-high-universal-health-coverage-levels-2/)
- [HTAi 14th Annual Meeting, Rome 2017, Report](https://www.costellomedical.com/news-and-views/articles-publications/htai-14th-annual-meeting-rome-2017/)
- [Costs and Effectiveness of Fingolimod Versus Alemtuzumab in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in the UK: Re-Treatment, Discount, and Disutility](https://www.costellomedical.com/news-and-views/articles-publications/costs-and-effectiveness-of-fingolimod-versus-alemtuzumab-in-the-treatment-of-highly-active-relapsing-remitting-multiple-sclerosis-in-the-uk-re-treatment-discount-and-disutility/)
- [Screening for Vasa Praevia in the Second Trimester of Pregnancy: External Review Against Programme Appraisal Criteria for the UK National Screening Committee (UK NSC)](https://www.costellomedical.com/news-and-views/articles-publications/screening-for-vasa-praevia-in-the-second-trimester-of-pregnancy-external-review-against-programme-appraisal-criteria-for-the-uk-national-screening-committee-uk-nsc/)
- [Long-Term Retention Rates for Anti-Epileptic Drugs: A Review of Long-Term Extension Studies and Comparison with Brivaracetam](https://www.costellomedical.com/news-and-views/articles-publications/long-term-retention-rates-for-antiepileptic-drugs-a-review-of-long-term-extension-studies-and-comparison-with-brivaracetam/)
- [Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease](https://www.costellomedical.com/news-and-views/articles-publications/challenges-associated-with-estimating-utility-in-wet-age-related-macular-degeneration-a-novel-regression-analysis-to-capture-the-bilateral-nature-of-the-disease/)
- [Exploring Concurrent Validity of The CLN2 Clinical Rating Scale: Comparison to PedsQL Using Mixed Effects Modelling and Data from a Phase 1/2 Single-Arm Trial](https://www.costellomedical.com/news-and-views/articles-publications/exploring-concurrent-validity-of-the-cln2-clinical-rating-scale-comparison-to-pedsql-using-mixed-effects-modelling-and-data-from-a-phase-1-2-single-arm-trial/)
- [Why Do ‘True’ Orphan Medicines Have Such a Low Acceptance Rate When Assessed by the SMC?](https://www.costellomedical.com/news-and-views/articles-publications/why-do-true-orphan-medicines-have-such-a-low-acceptance-rate-when-assessed-by-the-smc/)
- [An Exploration of the Methodology of Published Systematic Literature Reviews on “Burden of Disease”](https://www.costellomedical.com/news-and-views/articles-publications/an-exploration-of-the-methodology-of-published-systematic-literature-reviews-on-burden-of-disease/)
- [Model Types Submitted to NICE: What Is Considered Appropriate by Evidence Review Groups?](https://www.costellomedical.com/news-and-views/articles-publications/model-types-submitted-to-nice-what-is-considered-appropriate-by-evidence-review-groups/)
- [Does the NICE Diagnostics Assessment Programme Use an Empirical ICER Threshold?](https://www.costellomedical.com/news-and-views/articles-publications/does-the-nice-diagnostics-assessment-programme-use-an-empirical-icer-threshold/)
- [Payers, Politics and Pandemonium: An Insight into the Future UK Pricing and Market Access Environment](https://www.costellomedical.com/news-and-views/articles-publications/payers-politics-and-pandemonium-an-insight-into-the-future-uk-pricing-and-market-access-environment/)
- [An Audit of Evidence Review Group Criticisms of Systematic Literature Reviews Conducted to Inform Manufacturers’ Submissions to the National Institute for Health and Care Excellence](https://www.costellomedical.com/news-and-views/articles-publications/an-audit-of-evidence-review-group-criticisms-of-systematic-literature-reviews-conducted-to-inform-manufacturers-submissions-to-the-national-institute-for-health-and-care-excellence/)
- [When the Price Is Right: When, in Practice, Are Confidential Discounts Introduced in the NICE Process?](https://www.costellomedical.com/news-and-views/articles-publications/when-the-price-is-right-when-in-practice-are-confidential-discounts-introduced-in-the-nice-process/)
- [How Do NICE Evidence Review Groups Perceive Single Technology Appraisals Presenting Limited Evidence of Comparative Treatment Efficacy?](https://www.costellomedical.com/news-and-views/articles-publications/how-do-nice-evidence-review-groups-perceive-single-technology-appraisals-presenting-limited-evidence-of-comparative-treatment-efficacy/)
- [Health Technology Assessment in Singapore: Shining a Light in the Darkness](https://www.costellomedical.com/news-and-views/articles-publications/health-technology-assessment-in-singapore-shining-a-light-in-the-darkness/)
- [Consumer Comments in Health Technology Assessment in Australia: How Common and Influential Are They?](https://www.costellomedical.com/news-and-views/articles-publications/consumer-comments-in-health-technology-assessment-in-australia-how-common-and-influential-are-they/)
- [No EQ-5D? Analysis of Alternative Utility Value Sources Used in NICE Appraisals for Oncology Indications](https://www.costellomedical.com/news-and-views/articles-publications/no-eq-5d-analysis-of-alternative-utility-value-sources-used-in-nice-appraisals-for-oncology-indications/)
- [Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on HRQoL of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor](https://www.costellomedical.com/news-and-views/articles-publications/evaluating-matching-adjusted-indirect-comparison-and-simulated-treatment-comparison-techniques-impact-on-hrqol-of-focussed-ultrasound-thalamotomy-and-other-interventions-for-the-treatment-of-medicati/)
- [ISPOR 20th Annual European Congress, Glasgow 2017 Report](https://www.costellomedical.com/news-and-views/articles-publications/ispor-20th-annual-european-congress-glasgow-2017/)
- [Reporting of Delphi Methods to Achieve Consensus on Guidelines in Rare Diseases](https://www.costellomedical.com/news-and-views/articles-publications/reporting-of-delphi-methods-to-achieve-consensus-on-guidelines-in-rare-diseases/)
- [Rare Disease Publications: How Accessible Are They?](https://www.costellomedical.com/news-and-views/articles-publications/rare-disease-publications-how-accessible-are-they/)
- [Buzzwords in Highly-Cited Manuscript Abstracts](https://www.costellomedical.com/news-and-views/articles-publications/buzzwords-in-highly-cited-manuscript-abstracts/)
- [Costello Medical's MedTech Conference Roundup](https://www.costellomedical.com/news-and-views/articles-publications/costello-medicals-medtech-conference-roundup/)
- [Evidence in Support of Hyperkalaemia Management Strategies: A Systematic Literature Review](https://www.costellomedical.com/news-and-views/articles-publications/evidence-in-support-of-hyperkalaemia-management-strategies-a-systematic-literature-review/)
- [ISMPP European Meeting, London 2018, Congress Report](https://www.costellomedical.com/news-and-views/articles-publications/ismpp-european-meeting-london-2018/)
- [Costello Medical’s Attendance at SMi’s Orphan Drugs and Rare Diseases Conference](https://www.costellomedical.com/news-and-views/articles-publications/costello-medicals-attendance-at-smis-orphan-drugs-and-rare-diseases-conference/)
- [NICE Consultation on Proposed Changes to the Technology Appraisal Programme Phase 2](https://www.costellomedical.com/news-and-views/articles-publications/nice-consultation-on-proposed-changes-to-the-technology-appraisal-programme-phase-2/)
- [Costello Medical’s Attendance at the Findacure Drug Repurposing for Rare Diseases Conference 2018](https://www.costellomedical.com/news-and-views/articles-publications/costello-medicals-attendance-at-the-findacure-drug-repurposing-for-rare-diseases-conference-2018/)
- [Release of First Medical Device HTA Guidance in Singapore](https://www.costellomedical.com/news-and-views/articles-publications/release-of-first-medical-device-hta-guidance-in-singapore/)
- [Medical Affairs Leaders Forum 2018: Costello Medical's Roundup](https://www.costellomedical.com/news-and-views/articles-publications/medical-affairs-leaders-forum-2018-costello-medicals-roundup/)
- [Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and its Subcomponent Features](https://www.costellomedical.com/news-and-views/articles-publications/alkaptonuria-severity-score-index-revisited-analysing-the-akussi-and-its-subcomponent-features/)
- [Hot Topics from the European Conference on Rare Diseases and Orphan Products 2018](https://www.costellomedical.com/news-and-views/articles-publications/hot-topics-from-the-european-conference-on-rare-diseases-and-orphan-products-2018/)
- [Ask the Internet: Analysis of Online Discussions of Value Frameworks](https://www.costellomedical.com/news-and-views/articles-publications/ask-the-internet-analysis-of-online-discussions-of-value-frameworks/)
- [Systematic Review of the Clinical Efficacy of Vaginal Progesterone for Luteal Phase Support in Assisted Reproductive Technology Cycles](https://www.costellomedical.com/news-and-views/articles-publications/systematic-review-of-the-clinical-efficacy-of-vaginal-progesterone-for-luteal-phase-support-in-assisted-reproductive-technology-cycles/)
- [Focused Ultrasound Thalamotomy and Other Interventions for Medication-Refractory Essential Tremor: An Indirect Comparison of Short-Term Impact on Health-Related Quality of Life](https://www.costellomedical.com/news-and-views/articles-publications/focused-ultrasound-thalamotomy-and-other-interventions-for-medication-refractory-essential-tremor-an-indirect-comparison-of-short-term-impact-on-health-related-quality-of-life/)
- [Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults With Chronic Hepatitis C: A Systematic Literature Review and Meta-Analysis](https://www.costellomedical.com/news-and-views/articles-publications/health-state-utility-values-measured-using-the-euroqol-5-dimensions-questionnaire-in-adults-with-chronic-hepatitis-c-a-systematic-literature-review-and-meta-analysis/)
- [Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: A Cost‐Effectiveness Analysis](https://www.costellomedical.com/news-and-views/articles-publications/increasing-hepatitis-c-virus-screening-in-people-who-inject-drugs-in-switzerland-using-rapid-antibody-saliva-and-dried-blood-spot-testing-a-cost‐effectiveness-analysis/)
- [Comorbidities, Concomitant Medications and Potential Drug‐Drug Interactions with Interferon‐Free Direct‐Acting Antiviral Agents in Hepatitis C Patients in Taiwan](https://www.costellomedical.com/news-and-views/articles-publications/comorbidities-concomitant-medications-and-potential-drug‐drug-interactions-with-interferon‐free-direct‐acting-antiviral-agents-in-hepatitis-c-patients-in-taiwan/)
- [Medical Device Appraisal in the UK: What Are the Common Pitfalls of Manufacturer Literature Reviews?](https://www.costellomedical.com/news-and-views/articles-publications/medical-device-appraisal-in-the-uk-what-are-the-common-pitfalls-of-manufacturer-literature-reviews/)
- [Health Technology Assessment of mHealth Applications: Slow Progress in a Fast-Paced Industry?](https://www.costellomedical.com/news-and-views/articles-publications/health-technology-assessment-of-mhealth-applications-slow-progress-in-a-fast-paced-industry/)
- [Improving Patient and Financial Outcomes in the NHS: Early Arthritis Service Increases Patient Satisfaction Whilst Saving Costs](https://www.costellomedical.com/news-and-views/articles-publications/improving-patient-and-financial-outcomes-in-the-nhs-early-arthritis-service-increases-patient-satisfaction-whilst-saving-costs/)
- [Determining Factors for Decision-Making in the Medical Technologies Evaluation Programme](https://www.costellomedical.com/news-and-views/articles-publications/determining-factors-for-decision-making-in-the-medical-technologies-evaluation-programme/)
- [Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-Oncology Therapies in UK Technology Assessments](https://www.costellomedical.com/news-and-views/articles-publications/exploring-the-use-and-acceptance-of-alternative-survival-modelling-approaches-for-immuno-oncology-therapies-in-uk-technology-assessments/)
- [Evidence Development Timeline of Medical Devices in the UK:  Where do MedTech Innovation Briefings Fit?](https://www.costellomedical.com/news-and-views/articles-publications/evidence-development-timeline-of-medical-devices-in-the-uk-where-do-medtech-innovation-briefings-fit/)
- [Real World Data and Real World Evidence in Singapore: Are We Ready?](https://www.costellomedical.com/news-and-views/articles-publications/real-world-data-and-real-world-evidence-in-singapore-are-we-ready/)
- [Quality Assessment of Guidelines/Recommendations Developed using Delphi Methodology](https://www.costellomedical.com/news-and-views/articles-publications/quality-assessment-of-guidelines-recommendations-developed-using-delphi-methodology/)
- [Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting](https://www.costellomedical.com/news-and-views/articles-publications/modelling-the-impact-and-cost-effectiveness-of-extended-screening-and-treatment-with-direct-acting-antivirals-in-a-swiss-custodial-setting/)
- [Who’s Who in Rare Diseases: A Case Study in Author Identification](https://www.costellomedical.com/news-and-views/articles-publications/whos-who-in-rare-diseases-a-case-study-in-author-identification/)
- [Defining ‘White Paper’ Publications in the Peer-Reviewed Medical Literature](https://www.costellomedical.com/news-and-views/articles-publications/defining-white-paper-publications-in-the-peer-reviewed-medical-literature/)
- [Are Results from Human Factors Studies Communicated Consistently and Transparently?](https://www.costellomedical.com/news-and-views/articles-publications/are-results-from-human-factors-studies-communicated-consistently-and-transparently/)
- [How do Patients and Caregivers Access Scientific Literature?](https://www.costellomedical.com/news-and-views/articles-publications/how-do-patients-and-caregivers-access-scientific-literature/)
- [Thinking Ahead: The Evolution of Scientific Communication](https://www.costellomedical.com/news-and-views/articles-publications/ismpp-report-2019/)
- [Cross-Sectional Analysis of Phase I Clinical Trial Results Disclosure and Publication](https://www.costellomedical.com/news-and-views/articles-publications/cross-sectional-analysis-of-phase-i-clinical-trial-results-disclosure-and-publication/)
- [US and EU Patient Registries in the Peer-Reviewed Literature: A Targeted Review](https://www.costellomedical.com/news-and-views/articles-publications/us-and-eu-patient-registries-in-the-peer-reviewed-literature-a-targeted-review/)
- [Vax-The-Nation: A Budget Impact Analysis of Costs Associated with Measles Outbreaks in the USA Through Increasing Measles, Mumps and Rubella Vaccination Uptake](https://www.costellomedical.com/news-and-views/articles-publications/vax-the-nation-a-budget-impact-analysis-of-costs-associated-with-measles-outbreaks-in-the-usa-through-increasing-measles-mumps-and-rubella-vaccination-uptake/)
- [Expansion of State Medicaid Programs: Increased Patient Access to Opioid Replacement Therapy?](https://www.costellomedical.com/news-and-views/articles-publications/expansion-of-state-medicaid-programs-increased-patient-access-to-opioid-replacement-therapy/)
- [Framework Synthesis (FS) of Qualitative and Quantitative Evidence to Explore the Differential Diagnosis (DDx) of Diarrhea in Neuroendocrine Tumor (NET) Patients](https://www.costellomedical.com/news-and-views/articles-publications/framework-synthesis-fs-of-qualitative-and-quantitative-evidence-to-explore-the-differential-diagnosis-ddx-of-diarrhea-in-neuroendocrine-tumor-net-patients/)
- [What’s Trending? Pharmacoeconomic Publications in the US between 2009–2018](https://www.costellomedical.com/news-and-views/articles-publications/whats-trending-pharmacoeconomic-publications-in-the-us-between-2009-2018/)
- [Bundled Payments for Care Improvement Advanced (BPCI-A): An Analysis of Public Communications During the Application Period](https://www.costellomedical.com/news-and-views/articles-publications/bundled-payments-for-care-improvement-advanced-bpci-a-an-analysis-of-public-communications-during-the-application-period/)
- [Patient, Payer and Manufacturer Perspectives on Four Cost-Control Mechanisms for Pharmaceuticals](https://www.costellomedical.com/news-and-views/articles-publications/patient-payer-and-manufacturer-perspectives-on-four-cost-control-mechanisms-for-pharmaceuticals/)
- [Real-World Evidence on the Rise: Evaluating the Use of Real-World Evidence in ICER Assessments of Comparative Clinical Effectiveness](https://www.costellomedical.com/news-and-views/articles-publications/real-world-evidence-on-the-rise-evaluating-the-use-of-real-world-evidence-in-icer-assessments-of-comparative-clinical-effectiveness/)
- [Real-World Anti-viral Treatment Decisions Among Chronic Hepatitis C Patients in Taiwan: The INITIATE Study](https://www.costellomedical.com/news-and-views/articles-publications/real-world-anti-viral-treatment-decisions-among-chronic-hepatitis-c-patients-in-taiwan-the-initiate-study/)
- [Influencing ICER: A Review of Manufacturer Involvement in ICER Assessments](https://www.costellomedical.com/news-and-views/articles-publications/influencing-icer-a-review-of-manufacturer-involvement-in-icer-assessments/)
- [Associations Between Cognitive and Memory Problems, Employment and Quality of Life: A Survey of Epilepsy Patients in Australia](https://www.costellomedical.com/news-and-views/articles-publications/associations-between-cognitive-and-memory-problems-employment-and-quality-of-life-a-survey-of-epilepsy-patients-in-australia/)
- [Associations Between Comorbidities and Adverse Events of Antiepileptic Drugs and Quality of Life: A Survey of Epilepsy Patients in Australia](https://www.costellomedical.com/news-and-views/articles-publications/associations-between-comorbidities-and-adverse-events-of-antiepileptic-drugs-and-quality-of-life-a-survey-of-epilepsy-patients-in-australia/)
- [Is Delayed Access Due to Issues of HTA Capacity a Necessary Reality or an Unacceptable Problem?](https://www.costellomedical.com/news-and-views/articles-publications/is-delayed-access-due-to-issues-of-hta-capacity-a-necessary-reality-or-an-unacceptable-problem/)
- [Systematic Literature Review and Network Meta-analysis of Sodium-glucose Co-transporter Inhibitors vs Metformin as Add-on to Insulin in Type 1 Diabetes](https://www.costellomedical.com/news-and-views/articles-publications/systematic-literature-review-and-network-meta-analysis-of-sodium-glucose-co-transporter-inhibitors-vs-metformin-as-add-on-to-insulin-in-type-1-diabetes/)
- [Orphan Drug Compassionate Use Programmes: Impact on Reimbursement Decisions in France, Germany and England](https://www.costellomedical.com/news-and-views/articles-publications/orphan-drug-compassionate-use-programmes-impact-on-reimbursement-decisions-in-france-germany-and-england/)
- [Balancing Earlier Access and Data Immaturity – Are New Methods the Key?](https://www.costellomedical.com/news-and-views/articles-publications/balancing-earlier-access-and-data-immaturity-are-new-methods-the-key/)
- [A Formal System for Using Real-World Evidence to Revisit the HTA Decision: More Trouble Than It’s Worth?](https://www.costellomedical.com/news-and-views/articles-publications/a-formal-system-for-using-real-world-evidence-to-revisit-the-hta-decision-more-trouble-than-its-worth/)
- [Real-World Evidence in Gene Therapies: Recommendations Versus Reality](https://www.costellomedical.com/news-and-views/articles-publications/real-world-evidence-in-gene-therapies-recommendations-versus-reality/)
- [Accurate Predictions of Life Year Gains for Immuno-Oncology Therapies in the Long Term? An Analysis Based on Published Checkmate 057 Nivolumab Data](https://www.costellomedical.com/news-and-views/articles-publications/accurate-predictions-of-life-year-gains-for-immuno-oncology-therapies-in-the-long-term-an-analysis-based-on-published-checkmate-057-nivolumab-data/)
- [Parallel Scientific Advice from NICE and CADTH: Would One Submission Fit All?](https://www.costellomedical.com/news-and-views/articles-publications/parallel-scientific-advice-from-nice-and-cadth-would-one-submission-fit-all/)
- [To What Extent Does Seeking Clinical Expert Opinion for Model Inputs Reduce the Cost of Uncertainty? A Conceptual Approach Using Expected Value of Perfect Parameter Information (EVPPI)](https://www.costellomedical.com/news-and-views/articles-publications/to-what-extent-does-seeking-clinical-expert-opinion-for-model-inputs-reduce-the-cost-of-uncertainty-a-conceptual-approach-using-expected-value-of-perfect-parameter-information-evppi/)
- [Orphan Drug Compassionate Use Programmes: Scale of Use and Association with Regulatory and Reimbursement Decisions in France, Germany and the UK](https://www.costellomedical.com/news-and-views/articles-publications/orphan-drug-compassionate-use-programmes/)
- [Geographic Differences in the Growth of Open Access Publishing](https://www.costellomedical.com/news-and-views/articles-publications/geographic-differences-in-the-growth-of-open-access-publishing/)
- [Development, Validation and Concordance of Clinical Code Sets Used in Real-World Database Studies](https://www.costellomedical.com/news-and-views/articles-publications/development-validation-and-concordance-of-clinical-code-sets-used-in-real-world-database-studies/)
- [Trends in Patient-Focused Presentations at Scientific Congresses: A European Rheumatology Congress Case Study](https://www.costellomedical.com/news-and-views/articles-publications/trends-in-patient-focused-presentations-at-scientific-congresses-a-european-rheumatology-congress-case-study/)
- [Are Audiences Changing in the Digital Congress Era? Findings from Publicly Available Data](https://www.costellomedical.com/news-and-views/articles-publications/are-audiences-changing-in-the-digital-congress-era-findings-from-publicly-available-data/)
- [Impact of Generics and Biosimilars on Branded Drug Listing Decisions in Singapore](https://www.costellomedical.com/news-and-views/articles-publications/impact-of-generics-and-biosimilars-on-branded-drug-listing-decisions-in-singapore/)
- [Investigating Potential Market Failure with Curative Cell and Gene Therapies](https://www.costellomedical.com/news-and-views/articles-publications/investigating-potential-market-failure-with-curative-cell-and-gene-therapies/)
- [Healthcare Resource Use of People who use Illicit Opioids in England: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)](https://www.costellomedical.com/news-and-views/articles-publications/healthcare-resource-use-of-people-who-use-illicit-opioids-in-england-a-retrospective-cohort-study-using-clinical-practice-research-datalink-cprd-and-hospital-episode-statistics-hes/)
- [When Does “Access” Become “Established” in Rare Diseases?](https://www.costellomedical.com/news-and-views/articles-publications/when-does-access-become-established-in-rare-diseases/)
- [The Accessibility of Materials for Patients with Rare Diseases](https://www.costellomedical.com/news-and-views/articles-publications/the-accessibility-of-materials-for-patients-with-rare-diseases/)
- [Assessing the Impact of Twitter on Rare Disease Manuscript Citations and Altmetric Attention Scores](https://www.costellomedical.com/news-and-views/articles-publications/assessing-the-impact-of-twitter-on-rare-disease-manuscript-citations-and-altmetric-attention-scores/)
- [The NICE vs SMC Cost Comparison Pathways – How Similar are They?](https://www.costellomedical.com/news-and-views/articles-publications/the-nice-vs-smc-cost-comparison-pathways-how-similar-are-they/)
- [Examination of CMS National Coverage Analyses and Concordance with Other Decision-Making Bodies](https://www.costellomedical.com/news-and-views/articles-publications/examination-of-cms-national-coverage-analyses-and-concordance-with-other-decision-making-bodies/)
- [Survival Estimates Using Hazard Ratios Derived from Network Meta-Analyses: Exploratory Recommendations for Reference Curves](https://www.costellomedical.com/news-and-views/articles-publications/survival-estimates-using-hazard-ratios-derived-from-network-meta-analyses-exploratory-recommendations-for-reference-curves/)
- [A Case Study Using KEYNOTE-024 to Examine the Impact of Cut-Point Selection on Long-Term Survival Estimates from Piecewise Modeling](https://www.costellomedical.com/news-and-views/articles-publications/a-case-study-using-keynote-024-to-examine-the-impact-of-cut-point-selection-on-long-term-survival-estimates-from-piecewise-modeling/)
- [Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC as a Case Study](https://www.costellomedical.com/news-and-views/articles-publications/duration-and-timing-of-treatment-waning-determining-the-start-and-stop-points-using-pembrolizumab-in-nsclc-as-a-case-study/)
- [Influence of Metrics and Enhanced Content on Healthcare Professional Engagement with Publications](https://www.costellomedical.com/news-and-views/articles-publications/influence-of-metrics-and-enhanced-content-on-healthcare-professional-engagement-with-publications/)
- [The Recipe for Value Dossier Success: Should GenAI Be Added to the Mix?](https://www.costellomedical.com/news-and-views/articles-publications/the-recipe-for-value-dossier-success-should-genai-be-added-to-the-mix/)
- [Developing and Testing AI-Generated PICOS Summaries to Aid in Literature Reviews](https://www.costellomedical.com/news-and-views/articles-publications/developing-and-testing-ai-generated-picos-summaries-to-aid-in-literature-reviews/)
- [An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination with Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US](https://www.costellomedical.com/news-and-views/articles-publications/an-exploratory-cost-effectiveness-analysis-of-cancer-vaccines-in-combination-with-current-immune-checkpoint-inhibitors-vs-immune-checkpoint-inhibitor-monotherapy-a-case-study-for-v940-in-high-risk-st/)
- [From Approval to Publication: Study Types and Timeframes using the UK Clinical Practice Research Datalink](https://www.costellomedical.com/news-and-views/articles-publications/from-approval-to-publication-study-types-and-timeframes-using-the-uk-clinical-practice-research-datalink/)
- [How Do Healthcare Professionals Perceive Delphi Panels and Use Study Outcomes?](https://www.costellomedical.com/news-and-views/articles-publications/how-do-healthcare-professionals-perceive-delphi-panels-and-use-study-outcomes/)
- [Investigating the Quantitative Effect of Integrating Environmental Impacts into Economic Evaluations: To What Extent Could Environmental Sustainability Influence Decision Making in Health Technology Assessment?](https://www.costellomedical.com/news-and-views/articles-publications/investigating-the-quantitative-effect-of-integrating-environmental-impacts-into-economic-evaluations-to-what-extent-could-environmental-sustainability-influence-decision-making-in-health-technology-a/)
- [What Key Areas of Clinical and Economic Uncertainty Have Scottish Medicines Consortium (SMC) Identified in Ultra-Orphan Initial Assessments to Date?](https://www.costellomedical.com/news-and-views/articles-publications/what-key-areas-of-clinical-and-economic-uncertainty-have-scottish-medicines-consortium-smc-identified-in-ultra-orphan-initial-assessments-to-date/)
- [Navigating Prospective PICO Consolidation in Oncology: Insights from Retrospective Simulations for Crowded and Non-Crowded EU Treatment Landscapes](https://www.costellomedical.com/news-and-views/articles-publications/navigating-prospective-pico-consolidation-in-oncology-insights-from-retrospective-simulations-for-crowded-and-non-crowded-eu-treatment-landscapes/)
- [Are EU JCA Evidence Requirements Achievable? Insights from a Retrospective Evidence Analysis for Rare and Non-Rare EU Treatment Landscapes](https://www.costellomedical.com/news-and-views/articles-publications/are-eu-jca-evidence-requirements-achievable-insights-from-a-retrospective-evidence-analysis-for-rare-and-non-rare-eu-treatment-landscapes/)
- [Potential for Standardisation in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer](https://www.costellomedical.com/news-and-views/articles-publications/potential-for-standardisation-in-economic-assessment-across-hta-bodies-a-case-study-in-first-line-treatments-of-non-small-cell-lung-cancer/)
- [Capturing the Real-World Patient Perspective in HTA: Expert Patient Insights Lead to Robust Healthcare Cost and Resource Use Inputs for Cost-Effectiveness Model in SMA](https://www.costellomedical.com/news-and-views/articles-publications/capturing-the-real-world-patient-perspective-in-hta-expert-patient-insights-lead-to-robust-healthcare-cost-and-resource-use-inputs-for-cost-effectiveness-model-in-sma/)
- [A Review of Guidelines and Practices for Patient Involvement in HTA Across Europe, North America and APAC, to Identify Opportunities for Advancement in the Nascent Philippines HTA Market](https://www.costellomedical.com/news-and-views/articles-publications/a-review-of-guidelines-and-practices-for-patient-involvement-in-hta-across-europe-north-america-and-apac-to-identify-opportunities-for-advancement-in-the-nascent-philippines-hta-market/)
- [Accuracy of Life Year Gains Predictions for CAR-T Therapy in the Long Term: An Analysis for Axicabtagene Ciloleucelin Refractory Large B-Cell Lymphoma](https://www.costellomedical.com/news-and-views/articles-publications/accuracy-of-life-year-gains-predictions-for-car-t-therapy-in-the-long-term-an-analysis-for-axicabtageneciloleucelin-refractory-large-b-cell-lymphoma/)
- [Capturing The Value Of Potentially Curative Oncology Therapies: Lessons From The Use And Acceptance Of Cure Modelling Assumptions In NICE Technology Appraisals](https://www.costellomedical.com/news-and-views/articles-publications/capturing-the-value-of-potentially-curative-oncology-therapies-lessons-from-the-use-and-acceptance-of-cure-modelling-assumptions-in-nice-technology-appraisals/)
- [Examining the Effectiveness of the Cancer Drugs Fund: Are Data Collection Plans Working as Intended?](https://www.costellomedical.com/news-and-views/articles-publications/examining-the-effectiveness-of-the-cancer-drugs-fund/)
- [Publication Trends of Network Meta-analyses in Europe and Asia: A Focus on Cardiovascular Disease](https://www.costellomedical.com/news-and-views/articles-publications/publication-trends-of-network-meta-analyses-in-europe-and-asia-a-focus-on-cardiovascular-disease/)
- [Survival Estimates Using Hazard Ratios Derived From Network Meta-Analyses: Is More Guidance Needed?](https://www.costellomedical.com/news-and-views/articles-publications/survival-estimates-using-hazard-ratios-derived-from-network-meta-analyses-is-more-guidance-needed/)
- [Forecasting the Long-Term Treatment Effect Duration of Immuno-Oncology Therapies: An Analysis of the Predictive Accuracy of Treatment Waning Methods Applied to Pembrolizumab in Non-Small Cell Lung Cancer](https://www.costellomedical.com/news-and-views/articles-publications/forecasting-the-long-term-treatment-effect-duration-of-immuno-oncology-therapies/)
- [Does NICE’s New Severity Modifier Capture the Value of Treatments for Long-Term Progressive Diseases? A Retrospective Analysis of Past Appraisals in Multiple Sclerosis](https://www.costellomedical.com/news-and-views/articles-publications/does-nices-new-severity-modifier-capture-the-value-of-treatments-for-long-term-progressive-diseases-a-retrospective-analysis-of-past-appraisals-in-multiple-sclerosis/)
- [A Cost-Of-Illness Study of the Economic Burden of Obsessive-Compulsive Disorder in the United Kingdom](https://www.costellomedical.com/news-and-views/articles-publications/a-cost-of-illness-study-of-the-economic-burden-of-obsessive-compulsive-disorder-in-the-united-kingdom/)
- [Are Landmark Survival Models Accepted in National Institute for Health and Care Excellence Health Technology Evaluations?](https://www.costellomedical.com/news-and-views/articles-publications/are-landmark-survival-models-accepted-in-national-institute-for-health-and-care-excellence-health-technology-evaluations/)
- [Utility Studies in Rare Diseases: A Systematic Literature Review](https://www.costellomedical.com/news-and-views/articles-publications/utility-studies-in-rare-diseases-a-systematic-literature-review/)
- [Evaluating Trends in Use of Enhanced Publication Content](https://www.costellomedical.com/news-and-views/articles-publications/evaluating-trends-in-use-of-enhanced-publication-content/)
- [Demonstrating Similar or Greater Health Benefits Based on Indirect Evidence: A Review of NICE Evaluations that Included a Cost-Comparison Approach](https://www.costellomedical.com/news-and-views/articles-publications/demonstrating-similar-or-greater-health-benefits-based-on-indirect-evidence-a-review-of-nice-evaluations-that-included-a-cost-comparison-approach/)
- [Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence Updated Decision-Making Process?](https://www.costellomedical.com/news-and-views/articles-publications/benefits-not-captured-in-the-quality-adjusted-life-year-calculation-what-role-do-they-play-in-the-national-institute-for-health-and-care-excellence-updated-decision-making-process/)
- [Application of CPRD Data in NICE Submissions: Model Inputs for Functional Health States](https://www.costellomedical.com/news-and-views/articles-publications/application-of-cprd-data-in-nice-submissions-model-inputs-for-functional-health-states/)
- [Exploring The Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab Across Six Oncology Indications](https://www.costellomedical.com/news-and-views/articles-publications/exploring-the-predictive-accuracy-of-treatment-waning-methods-an-analysis-of-pembrolizumab-across-six-oncology-indications/)
- [Acceptance of Real-World Evidence as Comparative Efficacy in Lieu of Trial Evidence: A Review of Past NICE Appraisals in Oncology](https://www.costellomedical.com/news-and-views/articles-publications/acceptance-of-real-world-evidence-as-comparative-efficacy-in-lieu-of-trial-evidence-a-review-of-past-nice-appraisals-in-oncology/)
- [The NICE Medical Technologies Evaluation Programme (MTEP): An Analysis of Clinical and Economic Evidence Evaluated in Published Medical Technology Guidance](https://www.costellomedical.com/news-and-views/articles-publications/the-nice-medical-technologies-evaluation-programme-mtep-an-analysis-of-clinical-and-economic-evidence-evaluated-in-published-medical-technology-guidance/)
- [Reporting Patient Preference Studies in Health Technology Assessment Submissions: Does it Make a Difference?](https://www.costellomedical.com/news-and-views/articles-publications/reporting-patient-preference-studies-in-health-technology-assessment-submissions-does-it-make-a-difference/)
- [Flexsurv Methods to Estimate CuRe: An Exploration of Methods for Modelling Cure](https://www.costellomedical.com/news-and-views/articles-publications/flexsurv-methods-to-estimate-cure-an-exploration-of-methods-for-modelling-cure/)
- [A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis](https://www.costellomedical.com/news-and-views/articles-publications/a-targeted-literature-review-of-treatment-sequencing-approaches-in-economic-analyses-in-relapsing-multiple-sclerosis/)
- [Comparison of Prescription Drug Affordability Boards Across the United States](https://www.costellomedical.com/news-and-views/articles-publications/comparison-of-prescription-drug-affordability-boards-across-the-united-states/)
- [Digital Health Value Assessment Frameworks: An International Landscape](https://www.costellomedical.com/news-and-views/articles-publications/digital-health-value-assessment-frameworks-an-international-landscape/)
- [An Analysis of Manufacturer and Patient Engagement with Institute for Clinical and Economic Review Assessments](https://www.costellomedical.com/news-and-views/articles-publications/an-analysis-of-manufacturer-and-patient-engagement-with-institute-for-clinical-and-economic-review-assessments/)
- [Replicating Published Real-World Evidence Studies Using Electronic Medical Records From Community Hospitals](https://www.costellomedical.com/news-and-views/articles-publications/replicating-published-real-world-evidence-studies-using-electronic-medical-records-from-community-hospitals/)
- [A Case Study Using KEYNOTE-010 to Compare and Evaluate Long-Term Survival Estimates from Two Classes of Piecewise Models](https://www.costellomedical.com/news-and-views/articles-publications/a-case-study-using-keynote-010-to-compare-and-evaluate-long-term-survival-estimates-from-two-classes-of-piecewise-models/)
- [Health State Utility Value Elicitation in Medical Technology and Digital Health: How Do They Compare To Pharmaceuticals? A Targeted Literature Review of Interventions in Type 2 Diabetes Mellitus](https://www.costellomedical.com/news-and-views/articles-publications/health-state-utility-value-elicitation-in-medical-technology-and-digital-health-how-do-they-compare-to-pharmaceuticals-a-targeted-literature-review-of-interventions-in-type-2-diabetes-mellitus/)

## Pages

- [Home](https://www.costellomedical.com/) - Experts in the analysis, interpretation, and communication of clinical and health economic data
- [Operational Support – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/operational-support/)
- [News & Views](https://www.costellomedical.com/news-and-views/)
- [EU Joint Clinical Assessment (JCA)](https://www.costellomedical.com/what-we-do/value-and-access/joint-clinical-assessment/) - Discover how Costello Medical’s dedicated taskforce can support you with your EU Joint Clinical Assessment (JCA) submission.
- [Annabel's Legacy](https://www.costellomedical.com/force-for-good/annabels-legacy/)
- [Privacy Notice](https://www.costellomedical.com/privacy-notice/) - Who we are Our website address is: http://www.costellomedical.com. What personal data we collect and why we collect it Comments When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection. An anonymized string created from
- [Contact](https://www.costellomedical.com/contact/) - We are a rapidly-growing medical communication and health economic consultancy with offices in Cambridge, London, Singapore and Shanghai.
- [HTAi 2026 Insights: PALYs and PALE as Measures of Productivity Losses](https://www.costellomedical.com/what-we-do/value-and-access/hta/htai-2026-insights/) - Discover how PALYs and PALE are emerging as new ways to measure productivity losses in HTA and health economic evaluations beyond traditional QALYs.
- [Force For Good](https://www.costellomedical.com/force-for-good/)
- [Pro Bono](https://www.costellomedical.com/force-for-good/pro-bono/)
- [Careers](https://www.costellomedical.com/careers/) - We have ambitious plans for our future. Our future growth will continue to be shaped by our talented team. We are looking for individuals who are passionate about healthcare and who want to contribute to our mission and values.
- [Value & Access](https://www.costellomedical.com/what-we-do/value-and-access/) - Discover Costello Medical’s Value & Access services, shaping robust value propositions for HTA submissions, market access and health economics.
- [Rare Diseases at a European Crossroads: Which Way Forwards for Patients?](https://www.costellomedical.com/research/ispor-eu-event-2023/report/rare-diseases-at-a-european-crossroads/)
- [ISPOR Europe 2025 Report](https://www.costellomedical.com/research/ispor-eu-event-2025/report/)
- [ISPOR Europe 2024 Report](https://www.costellomedical.com/research/ispor-eu-event-2024/report/)
- [Technical Innovation & AI](https://www.costellomedical.com/what-we-do/technical-innovation-and-ai/)
- [ISMPP EU Report 2025](https://www.costellomedical.com/research/ismpp-eu-event-2025/report/)
- [ISPOR International 2025 Report](https://www.costellomedical.com/research/ispor-international-event-2025/report/)
- [Statistics](https://www.costellomedical.com/what-we-do/evidence-development/statistics/) - Delivering clinically appropriate, data-driven results is the underlying principle of all projects undertaken by the Statistics Team at Costello Medical.
- [ISPOR International Report 2024](https://www.costellomedical.com/research/ispor-us-event-2024/report/)
- [ISPOR EU Report 2023](https://www.costellomedical.com/research/ispor-eu-event-2023/report/)
- [ISPOR Europe 2023](https://www.costellomedical.com/research/ispor-eu-event-2023/)
- [Costello Medical Is Now Employee-Owned](https://www.costellomedical.com/about-us/employee-ownership-trust/)
- [About Us](https://www.costellomedical.com/about-us/) - Due to the demand across an increasing range of service offerings and geographies, Costello Medical has grown organically since foundation in 2008 to become one of the most established independent agencies delivering medical communications and health economic services.
- [Articles & Publications](https://www.costellomedical.com/news-and-views/articles-publications/) - We are dedicated to contributing novel research across all our areas of expertise. Please view our research and publications.
- [Whether, When and How to EU JSC](https://www.costellomedical.com/what-we-do/value-and-access/whether-when-and-how-to-eu-jsc-2026/) - Watch this webinar to gain practical insights into the the realities of preparing for and conducting an EU JSC, based on Costello Medical's experience
- [Global Health – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/global-health-call-for-projects/)
- [R for Health Technology Assessment 2026: Key HEOR Insights](https://www.costellomedical.com/what-we-do/value-and-access/hta/key-heor-insights/) - Explore Costello Medical’s biggest takeaways from R for Health Technology Assessment 2026, including Excel/R hybrid models, AI adoption and upskilling in HEOR.
- [MedComms in the New Digital Era: Insights from SXSW London](https://www.costellomedical.com/what-we-do/medical-communications/creative/insights-sxsw-london-2026/)
- [Incorporation of Minimally Important Differences in Network Meta-Analysis](https://www.costellomedical.com/what-we-do/evidence-development/statistics/minimally-important-differences-network-meta-analysis/) - Explore the use of minimally important differences in network meta-analysis for health technology assessment.
- [How the 10 Year Health Plan Could Transform Real-World Evidence in the UK](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/nhs-10-year-health-plan/) - Read our insights into how the NHS 10 Year Health Plan for England could transform real-world evidence, data access, and patient-centred research in HTA.
- [Elevating Value Dossiers with Patient-Centric Strategies](https://www.costellomedical.com/what-we-do/value-and-access/patient-centric-value-dossiers/) - How to elevate value dossiers with patient-centric strategies: Embedding patient perspectives and accessible, decision-ready evidence for HTA and reimbursement.
- [Evidence Development](https://www.costellomedical.com/what-we-do/evidence-development/) - Elevate your research with Costello Medical’s Evidence Development services: Expert statistics, comprehensive literature reviews, and robust real-world evidence.
- [Delphi Panels](https://www.costellomedical.com/what-we-do/evidence-development/delphi-panels/) - Discover Delphi panels by Costello Medical: Expert consensus methods, survey execution, web app-enabled analysis, and peer-reviewed results across diseases.
- [Real-World Evidence](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/) - Explore Costello Medical’s Real-World Evidence services, including bespoke study design, data source mapping, and support across the product lifecycle.
- [The Dawn of Real-World Evidence Frameworks: Where Does NICE Fit In?](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence-frameworks-nice/) - Discover how the NICE Real-World Evidence Framework shapes real-world data use in health decisions and practice.
- [Public Consultation on Including Technology Appraisal Guidance in NICE Guidelines](https://www.costellomedical.com/what-we-do/value-and-access/hta/public-consultation-on-including-technology-appraisal-guidance-in-nice-guidelines/) - Costello Medical's view on NICE's Incorporation vs Integration of technology appraisal guidance, featuring insights from the public consultation.
- [NICE’s ‘Proportionate Approach to Technology Appraisals'](https://www.costellomedical.com/what-we-do/value-and-access/hta/nices-proportionate-approach-to-technology-appraisals/) - Explore Costello Medical’s views on NICE's Proportionate Approach to Technology Appraisals: changes, challenges, and practical guidance for industry.
- [Better Together: The Impact of Joint Clinical Assessments on Systematic Literature Reviews](https://www.costellomedical.com/what-we-do/value-and-access/impact-of-joint-clinical-assessments/) - Discover Costello Medical’s insights into JCAs' impact on systematic literature review scope, PICO definitions, and reporting transparency to streamline EU HTA.
- [ISPOR 2026 Report](https://www.costellomedical.com/research/ispor-2026/report/)
- [Asking the Right Question First: Reflections on Estimand Discipline and the Future of Multivariate Methods](https://www.costellomedical.com/research/ispor-2026/report/estimand-discipline-multivariate-methods/) - How clear estimands align regulatory and HTA needs, reduce ambiguity in patient‑reported outcomes, and enable robust multivariate evidence synthesis.
- [The AI Literature Review Dilemma: Commercial Momentum vs Best Practice Guidelines](https://www.costellomedical.com/research/ispor-2026/report/ai-literature-review-dilemma/) - Discover how commercial momentum around AI-assisted literature review platforms contrasts with cautious best-practice guidelines and HTA expectations.
- [Is Global Evidence Generation Entering a China-Led Era?](https://www.costellomedical.com/research/ispor-2026/report/global-evidence-china-led-era/) - Costello Medical explores how China’s rapid trials and RWE for NRDL decisions could reshape global market access strategies.
- [Rare Disease Research Has a Data Problem. Digital Tools Are Not the Solution, But They Might Be the Start](https://www.costellomedical.com/research/ispor-2026/report/rare-disease-data-problem/) - Exploring rare disease data sources, from digital tools to EHRs, shows their value for signal detection, but also why they must not replace clinical evidence.
- [MFN Through the Lens of Dynamic Efficiency](https://www.costellomedical.com/research/ispor-2026/report/mfn-dynamic-efficiency/) - Explore how MFN drug pricing interacts with dynamic efficiency and global free‑rider problems, and why country‑specific value‑based pricing matters.
- [Brave New World: The Spreading Uncertainty Within the US Healthcare Landscape](https://www.costellomedical.com/research/ispor-2026/report/us-healthcare-uncertainty/) - Costello Medical unpacks growing uncertainty in US healthcare as overlapping drug pricing policies impact market access and reimbursement.
- [ISPOR 2026](https://www.costellomedical.com/research/ispor-2026/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [Public Consultation on NICE Integrated Topic Prioritisation and Strategic Principles](https://www.costellomedical.com/what-we-do/value-and-access/hta/public-consultation-on-nice-integrated-topic-prioritisation-and-strategic-principles/) - Discover Costello Medical’s insights into NICE’s Integrated Topic Prioritisation and Strategic Principles, including changes, eligibility, and decision-making.
- [Patient Engagement in HTA](https://www.costellomedical.com/what-we-do/value-and-access/hta/patient-engagement-in-hta/) - Discover Costello Medical's guide for pharmaceutical companies submitting to NICE, detailing potential patient involvement in the single technology assessment process.
- [Health Inequalities: NICE Takes a Step Forward](https://www.costellomedical.com/what-we-do/value-and-access/hta/health-inequalities/) - Explore Costello Medical's insights on the NICE health inequalities modular update, DCEA guidance, and the implications for HTA transparency.
- [Catalyst for Change or Status Quo? Reflections on TSD 26 on Expert Elicitation](https://www.costellomedical.com/what-we-do/value-and-access/hta/tsd26-expert-elicitation-reflections/) - Discover Costello Medical’s perspective on NICE TSD26 and structured expert elicitation for long-term survival in oncology HTAs.
- [HTA](https://www.costellomedical.com/what-we-do/value-and-access/hta/) - Having supported our clients with over 80 HTA submissions, our dedicated HTA team are the experts when it comes to devising the optimal strategy and delivering the highest quality dossiers.
- [Health Economics](https://www.costellomedical.com/what-we-do/value-and-access/health-economics/) - Our Health Economics team tailors complex global and HTA-ready cost-effectiveness models, local budget impact models and user-friendly market access tools to fit your needs.
- [Market Access](https://www.costellomedical.com/what-we-do/value-and-access/market-access/) - We focus on demonstrating the value of a product using the strongest scientific evidence base available, but nowhere is this emphasis more evident than in our market access work.
- [Navigating the Challenges of Joint Clinical Assessment for Advanced Therapy Medicinal Products](https://www.costellomedical.com/what-we-do/value-and-access/challenges-for-advanced-therapy-medicinal-products/) - Explore EU Joint Clinical Assessment for ATMPs and rare-disease HTA: harmonising assessments across member states and the practical challenges for manufacturers.
- [Ready for EU Joint Clinical Assessment (JCA): Key Reflections from 2024 & Important Unknowns](https://www.costellomedical.com/what-we-do/value-and-access/jca-2024-key-reflections/) - Read Costello Medical’s insights on EU Joint Clinical Assessment: Timelines, PICOs, real-world evidence, and questions we’re tracking as JCA unfolds.
- [Data Detectives: Overcoming the Challenges of a Rare Disease Evidence Base to Develop a Compelling Value Narrative](https://www.costellomedical.com/what-we-do/value-and-access/rare-disease-compelling-narrative/) - Explore Costello Medical’s strategies to turn a sparse rare disease evidence base into a compelling value narrative with early planning and stakeholder engagement.
- [Review of Guidelines for Direct & Indirect Comparisons for JCA](https://www.costellomedical.com/what-we-do/value-and-access/review-of-guidelines-for-direct-and-indirect-comparisons-for-jca/) - Explore EU Joint Clinical Assessment guidelines on direct and indirect comparisons, with cautious interpretation and time‑pressured SLR considerations.
- [The Critical Role of the Global Value Dossier in EU Joint Clinical Assessment](https://www.costellomedical.com/what-we-do/value-and-access/role-of-the-global-value-dossier/) - Explore Costello Medical’s Global Value Dossier insights for EU Joint Clinical Assessment: PICO-focused, two-phase development, and HTA guidance.
- [The Joint Clinical Assessment Dossier: A Fresh Approach or Business as Usual?](https://www.costellomedical.com/what-we-do/value-and-access/the-jca-dossier-fresh-approach-or-business-as-usual/) - Costello Medical’s insights on JCA dossiers: evaluating EU-wide HTA, template parallels with G-BA/NICE, and practical preparation for multi-PICO submissions.
- [Unlocking Value: 5 Top Tips for a Winning Value Dossier](https://www.costellomedical.com/what-we-do/value-and-access/top-tips-value-dossier/) - Read Costello Medical’s top 5 tips for creating robust value dossiers, including concise content, early planning and adaptable templates for market access.
- [Value Dossiers for MedTech: Back to the Drawing Board?](https://www.costellomedical.com/what-we-do/value-and-access/value-dossier-medtech/) - Explore how the differences between pharmaceutical and MedTech industries shape your value dossier, addressing key challenges and recommended strategies.
- [The Impact of RSV Vaccine Rollout in England](https://www.costellomedical.com/what-we-do/evidence-development/infectious-disease-modelling/impact-of-rsv-vaccine-england/) - Discover the impact of the older adult RSV vaccination rollout in England, focusing on vaccine uptake and its effect on RSV-related hospitalisations.
- [Infectious Disease Report](https://www.costellomedical.com/what-we-do/evidence-development/infectious-disease-modelling/reports/) - Register your interest in Costello Medical’s Infectious Disease Modelling reports and receive updates on our infectious disease services.
- [Real-World Data Source Mapping](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/real-world-data-source-mapping/) - Explore Costello Medical’s Real-World Data Source Mapping services to map, assess, and compare data sources for credible, regulatory-aligned evidence.
- [Unquantified Insights: An Assessment of NICE’s Qualitative Research Appendix](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/nice-qualitative-research-appendix/) - Explore how the NICE qualitative research appendix strengthens decision-making in health technology assessments through qualitative insights.
- [Navigating the Data Wilderness: Best Practices in Real-World Data Source Landscaping](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/navigating-data-wilderness/) - Discover how to navigate real-world data landscapes using bespoke source mapping, risk-adjusted trade-offs, and decision-ready evidence.
- [Crossing Borders, Bridging Gaps: Can Data Transportability Connect Patients to Therapies Faster?](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/data-transportability-in-real-world-evidence/) - Explore data transportability in real-world evidence: how transported real-world data addresses gaps, improves generalisability, and informs decisions.
- [Qualitative Research](https://www.costellomedical.com/what-we-do/evidence-development/real-world-evidence/qualitative-research/) - Discover Costello Medical’s qualitative research capabilities to uncover the experiences of your stakeholders, including patients and healthcare professionals.
- [AI in Literature Reviews: Maximising Benefits, Reducing Harms](https://www.costellomedical.com/what-we-do/evidence-development/literature-reviews/ai-in-literature-reviews/) - Discover how AI can be used in literature reviews to boost efficiency while preserving rigour and human oversight.
- [Innovating Literature Reviews with AI: Our Approach](https://www.costellomedical.com/what-we-do/evidence-development/literature-reviews/innovating-literature-reviews-with-ai/) - Discover our approach to using AI in literature reviews: evaluating prompts for data extraction, RCT/economic data, and integration into our review platform.
- [Literature Reviews](https://www.costellomedical.com/what-we-do/evidence-development/literature-reviews/) - Our dedicated Literature Reviews team has extensive experience across a variety of literature searching methodologies for diverse purposes.
- [Artificial Intelligence in Network Meta-Analysis for HTA](https://www.costellomedical.com/what-we-do/evidence-development/statistics/ai-network-meta-analysis-hta/) - Explore the role of artificial intelligence in network meta-analysis through the lens of a case study.
- [Systematic Literature Reviews: An Exercise in Compromise?](https://www.costellomedical.com/what-we-do/evidence-development/systematic-literature-reviews/) - Discover how prioritisation can strengthen a systematic literature reviews’ focus, timeliness, and impact.
- [In Defence of the Targeted Literature Review](https://www.costellomedical.com/what-we-do/evidence-development/targeted-literature-review/) - Discover our practical insights on when to use targeted reviews vs. systematic literature reviews to balance speed, cost and rigour in evidence synthesis.
- [Working At Costello Medical](https://www.costellomedical.com/careers/working-at-costello-medical/)
- [Career Profiles](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/)
- [Molly Atkinson](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/molly-atkinson/)
- [Emma Phillips](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/emma-phillips/)
- [Dan Garlick](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/dan-garlick/)
- [Naomi van Hest](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/naomi-van-hest/)
- [Key Questions Ahead of the First EU JCA Reports](https://www.costellomedical.com/what-we-do/value-and-access/key-questions-first-eu-jca-reports/)
- [Day in the Life of a Senior Analyst in Market Access](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-senior-analyst-market-access/)
- [Digital Design](https://www.costellomedical.com/what-we-do/medical-communications/creative/digital-design/)
- [Women's Health – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/womens-health/)
- [Global Health Internship](https://www.costellomedical.com/force-for-good/global-health-internship/) - The Costello Medical Global Health Internship aims to provide a long-term solution to the need for evidence-based health policies and treatments in low- or middle-income countries.
- [Rare Diseases](https://www.costellomedical.com/what-we-do/rare-diseases/) - Understanding the unique challenges facing the rare diseases industry is what underpins the specialised approach of the multidisciplinary team dedicated to rare diseases at Costello Medical. 
- [Changes to the UK Rare Disease Landscape in 2026](https://www.costellomedical.com/what-we-do/rare-diseases/uk-rare-disease-landscape-changes-2026/)
- [Patient Engagement](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/patient-engagement/)
- [The Commercial Value of Patient Engagement](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/patient-engagement/patient-engagement-commercial-value/)
- [Annual Reports](https://www.costellomedical.com/about-us/annual-reports/)
- [Women+ Health – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/women-plus-health/)
- [Creative](https://www.costellomedical.com/what-we-do/medical-communications/creative/)
- [B Corp](https://www.costellomedical.com/force-for-good/b-corp/)
- [Team](https://www.costellomedical.com/about-us/team/) - With exceptionally talented staff who have experience across a broad range of therapy areas, we have the expertise to successfully support healthcare interventions throughout their entire lifecycle in many different settings. 
- [ISMPP EU 2026](https://www.costellomedical.com/research/ismpp-eu-event-2026/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [Gene Therapy](https://www.costellomedical.com/what-we-do/gene-therapy/)
- [What Does the ITC Toolkit Look Like in the JCA Era?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/itc-toolkit-in-jca-era/)
- [ISPOR Europe 2025](https://www.costellomedical.com/research/ispor-eu-event-2025/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [Walking the Walk – Translating Vision into Reality for Patient-Centred Healthcare Decision-Making](https://www.costellomedical.com/research/ispor-eu-event-2025/report/walking-the-walk/)
- [AI in Literature Reviews: Hype or Helpful?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/ai-litrevs-hype-or-helpful/)
- [Should Environmental Considerations be Captured in HTAs?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/environmental-considerations-in-htas/)
- [EU JCA: Are we Entering the Trough of Disillusionment?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/entering-trough-of-disillusionment/)
- [Is There More to AI in HEOR Than Literature Reviews?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/is-there-more-to-ai-in-heor/)
- [The HEMA Draft Report: Is it Enough?](https://www.costellomedical.com/research/ispor-eu-event-2025/report/hema-draft-report/)
- [Infectious Disease Modelling](https://www.costellomedical.com/what-we-do/evidence-development/infectious-disease-modelling/) - Explore our infectious disease modelling services, combining epidemiological expertise with data sourcing, modelling, and reporting for comprehensive support.
- [Locations](https://www.costellomedical.com/careers/locations/)
- [Value Assessment Frameworks Fit for the Digital Age](https://www.costellomedical.com/research/ispor-eu-event-2023/report/value-assessment-frameworks-fit-for-the-digital-age/)
- [PICO Simulation for Rare Disease Medicines: Practical Recommendations for Successful JCA Preparations](https://www.costellomedical.com/what-we-do/rare-diseases/pico-simulation-rare-disease-jca-preparations/)
- [Industry Spotlight: Health Economic Modelling in MedTech](https://www.costellomedical.com/what-we-do/medtech/economic-modelling-medtech/)
- [MedTech](https://www.costellomedical.com/what-we-do/medtech/) - Our MedTech consultancy team provide market access, HEOR and medical communications expertise for medical devices, diagnostics and digital health
- [The Annabel Griffiths Rare Disease Project](https://www.costellomedical.com/force-for-good/pro-bono/annabel-griffiths-rare-disease-project/)
- [The Role of Patients in Scientific Congresses: Benefits, Challenges and Future Opportunities](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/patient-engagement/patients-in-scientific-congresses/)
- [Whistleblowing & Grievance Reporting](https://www.costellomedical.com/whistleblowing-and-grievance-reporting/)
- [What's this Button for? Digital Health is Being Held to a Higher Standard](https://www.costellomedical.com/research/ispor-us-event-2024/report/digital-health/)
- [Ignorance is not Bliss: The Value of Diagnostics in the Absence of Optimal Therapies](https://www.costellomedical.com/research/ispor-us-event-2024/report/value-of-diagnostics/)
- [To Incentivise a “Whole Health” Approach, We Need to Fix the "Wrong Pocket Problem"](https://www.costellomedical.com/research/ispor-us-event-2024/report/incentivising-whole-health-approach/)
- [Overcoming Hesitancy to Include Real-World Evidence (RWE) in Reimbursement Submissions](https://www.costellomedical.com/research/ispor-us-event-2024/report/real-world-evidence-in-reimbursement-submissions/)
- [IRA and US Drug Price Negotiations](https://www.costellomedical.com/research/ispor-us-event-2024/report/ira-and-us-drug-price-negotiations/)
- [From Promise to Practice: The Evolving Role of GenAI in HEOR](https://www.costellomedical.com/research/ispor-us-event-2024/report/the-evolving-role-of-genai-in-heor/)
- [Advancing Statistical Methods: Innovations at ISPOR 2024](https://www.costellomedical.com/research/ispor-us-event-2024/report/advancing-statistical-methods/)
- [Day in the Life of a Senior Medical Writer (US)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-senior-medical-writer-us/)
- [Analytical Methods and Technical Topics](https://www.costellomedical.com/research/ispor-us-report-2022/analytical-methods-and-technical-topics/)
- [Unlocking AI’s Potential in Value & Access Writing](https://www.costellomedical.com/what-we-do/value-and-access/unlocking-ai-potential-value-access/) - Read our guide to using GenAI in value and access writing: efficiency gains, the importance of human review, and health technology assessment alignment.
- [From Trendy to Timeless: Sustaining Patient Access to Rare Disease Therapies in a Shifting Landscape](https://www.costellomedical.com/research/ispor-eu-event-2024/report/patient-access-rare-disease-therapies/)
- [The Bigger Picture: Considering Broader Value Drivers and Perspectives in HEOR](https://www.costellomedical.com/research/ispor-eu-event-2024/report/broader-value-drivers-and-perspectives-in-heor/)
- [How Can We Navigate Uncertainty in Comparative Effectiveness Analyses? - Advances in Statistical Techniques for HTA](https://www.costellomedical.com/research/ispor-eu-event-2024/report/advances-in-statistical-techniques/)
- [RWE and HTA for Diagnostics and Devices](https://www.costellomedical.com/research/ispor-eu-event-2024/report/rwe-medical-devices-diagnostics/)
- [Will JCA Set the Tempo For Increased Global Harmonisation in the Access Landscape?](https://www.costellomedical.com/research/ispor-eu-event-2024/report/jca-increased-global-harmonisation/)
- [The Home Stretch: Is Europe Any More Ready for the HTAR One Year On?](https://www.costellomedical.com/research/ispor-eu-event-2024/report/europe-htar-ready/)
- [Trust Me I’m a (Ph)Doctor: Ensuring Integrity and Reliability in AI-Augmented HEOR Work](https://www.costellomedical.com/research/ispor-eu-event-2024/report/ai-augmented-heor/)
- [US Healthcare Policy in Flux – What We Know & Don’t Know](https://www.costellomedical.com/research/ispor-international-event-2025/report/us-healthcare-policy-in-flux/)
- [Revolutionising Rare Disease Data Generation](https://www.costellomedical.com/research/ispor-international-event-2025/report/rare-disease-data-generation/)
- [Like It or Not, It’s Here to Stay: AI Applications in HEOR](https://www.costellomedical.com/research/ispor-international-event-2025/report/ai-applications-in-heor/)
- [Literature Reviews – The Promised ‘Low-Hanging Fruit’ Application of AI in HEOR?](https://www.costellomedical.com/research/ispor-international-event-2025/report/ai-in-heor-literature-reviews/)
- [What We Do](https://www.costellomedical.com/what-we-do/) - Our expert cross-functional teams work seamlessly alongside our clients to achieve success in both strategic planning and project execution across the key services
- [HEOR for All: Methodological Advancements to Promote Inclusivity and Equity in Healthcare Decision-Making](https://www.costellomedical.com/research/ispor-international-event-2025/report/heor-healthcare-inclusivity-and-equity/)
- [ISPOR International 2025](https://www.costellomedical.com/research/ispor-international-event-2025/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [Graphic Design in MedComms: Decoding Complex Information](https://www.costellomedical.com/what-we-do/medical-communications/creative/graphic-design-in-medcomms/)
- [ISMPP EU Report 2023](https://www.costellomedical.com/research/ismpp-eu-report-2023/)
- [ISMPP EU Report 2024](https://www.costellomedical.com/research/ismpp-eu-report-2024/)
- [AMCP 2022 Report](https://www.costellomedical.com/research/amcp-2022-report/)
- [AMCP 2023 Report](https://www.costellomedical.com/research/amcp-2023-report/)
- [ABHI UK HealthTech Conference 2023 Round-up](https://www.costellomedical.com/research/abhi-uk-healthtech-conference-2023/)
- [The Role of Digital Design in Medical Communications](https://www.costellomedical.com/what-we-do/medical-communications/creative/digital-design/digital-design-in-medical-communications/)
- [Revisions to NICE’s Highly Specialised Technologies Routing Criteria: What Will These Mean for Future Ultra-Orphan Technologies?](https://www.costellomedical.com/what-we-do/rare-diseases/revisions-to-nices-highly-specialised-technologies-routing-criteria/)
- [Updates to NICE Methods and Processes](https://www.costellomedical.com/what-we-do/rare-diseases/updates-to-nice-methods-and-processes/)
- [Navigating Diverse Educational Needs in MedTech](https://www.costellomedical.com/what-we-do/medtech/diverse-educational-needs-medtech/) - So, what is the recipe for success? We’ve delivered scores of dossiers, so here are our top 5 tips
- [Opinions on the NICE HealthTech Programme Consultation](https://www.costellomedical.com/what-we-do/medtech/nice-healthtech-programme-consultation/)
- [Public Engagement on Building an Integrated, Rules-Based Medical Technology (MedTech) Pathway in England](https://www.costellomedical.com/what-we-do/medtech/rules-based-pathway/) - What does the NHS England and NICE Integrated, Rules-Based MedTech Pathway mean for you? Navigate this new framework's opportunities and challenges
- [Beyond the Static: Motion Design Brings Healthcare to Life](https://www.costellomedical.com/what-we-do/medical-communications/creative/motion-design-brings-healthcare-to-life/)
- [Mental Health – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/mental-health/)
- [Public Sector](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/public-sector/) - We are enthusiastically dedicated to the delivery of effective healthcare, but we recognise that commercial channels are not the only route by which this goal is being realised.
- [Health Policy](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/health-policy/) - Our Health Policy team provides end-to-end support for the delivery of impactful, evidence-based health policy projects.
- [Publications](https://www.costellomedical.com/what-we-do/medical-communications/publications/) - We believe that high-quality, evidence-based publications support new, innovative treatments and improved patient care.
- [Medical Affairs](https://www.costellomedical.com/what-we-do/medical-communications/medical-affairs/) - The effective practice of medical affairs is essential for the generation and communication of relevant evidence to a broad range of stakeholders across the healthcare environment.
- [Benefits Package in the UK](https://www.costellomedical.com/careers/working-at-costello-medical/benefits-package-in-the-uk/)
- [Benefits Package in the US](https://www.costellomedical.com/careers/working-at-costello-medical/benefits-package-in-the-us/)
- [Benefits Package in Singapore](https://www.costellomedical.com/careers/working-at-costello-medical/benefits-package-in-singapore/)
- [Benefits Package in China](https://www.costellomedical.com/careers/working-at-costello-medical/benefits-package-in-china/)
- [Medical Communications](https://www.costellomedical.com/what-we-do/medical-communications/)
- [Community](https://www.costellomedical.com/force-for-good/community/)
- [Health Policy & Public Affairs](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/)
- [Eleanor Thurtle](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/eleanor-thurtle/)
- [Audrey Artignan](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/audrey-artignan/)
- [William Marsh](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/william-marsh/)
- [Amy Buchanan-Hughes](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/amy-buchanan-hughes/)
- [Gallia Goddard](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/gallia-goddard/)
- [Patsy Silvester](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/patsy-silvester/)
- [Emma King](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/emma-king/)
- [Eve McArthur](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/eve-mcarthur/)
- [Debbie Baker](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/debbie-baker/)
- [Charlotte Bright](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/charlotte-bright/)
- [Georgina Skells](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/georgina-skells/)
- [Aaditya Rawal](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/aaditya-rawal/)
- [Alex Pashley](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/alex-pashley/)
- [Day in the Life of a Senior Analyst in HTA](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-senior-analyst-hta/)
- [Day in the Life of a Pro Bono Analyst](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-pro-bono-analyst/)
- [Day in the Life of a Global Health Intern](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-global-health-intern/)
- [Day in the Life of a Bilingual Analyst (Singapore)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-bilingual-analyst-singapore/)
- [Day in the Life of an Analyst/Medical Writer Intern](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-analyst-medical-writer-intern/)
- [Day in the Life of a Digital Designer](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-digital-designer/)
- [Day in the Life of a Statistician (Singapore)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-statistician-singapore/)
- [Day in the Life of a Graphic Designer](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-graphic-designer/)
- [Day in the Life of a Health Economist (Singapore)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-health-economist-singapore/)
- [Day in the Life of a Project Coordinator](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-project-coordinator/)
- [Day in the Life of an Analyst](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-analyst/)
- [Day in the Life of a Statistician](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-statistician/)
- [Day in the Life of a Developer](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-developer/)
- [Day in the Life of a Health Economist](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-health-economist/)
- [Day in the Life of a Personal Assistant](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-personal-assistant/)
- [Day in the Life of a Facilities Administrator](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-facilities-administrator/)
- [Day in the Life of a Senior Analyst (US)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-senior-analyst-us/)
- [Day in the Life of an IT Administrator](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-it-administrator/)
- [Day in the Life of an Analyst (Singapore)](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-analyst-singapore/)
- [Day in the Life of a Medical Writer](https://www.costellomedical.com/careers/working-at-costello-medical/day-in-the-life-medical-writer/)
- [Bo Lyu](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/bo-lyu/)
- [Holly Cornell](https://www.costellomedical.com/careers/working-at-costello-medical/career-profiles/holly-cornell/)
- [Case Studies](https://www.costellomedical.com/what-we-do/case-studies/)
- [Alumni Network](https://www.costellomedical.com/alumni-network/)
- [ISMPP EU 2025](https://www.costellomedical.com/research/ismpp-eu-event-2025/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [AI in HEOR: Pathways, Challenges and Future Directions](https://www.costellomedical.com/research/ispor-eu-event-2023/report/ai-in-heor-pathways-challenges-and-future-directions/)
- [FAQs](https://www.costellomedical.com/careers/faqs/)
- [Get In Touch](https://www.costellomedical.com/get-in-touch/)
- [Equity & Inclusion](https://www.costellomedical.com/force-for-good/equity-and-inclusion/)
- [Working in London](https://www.costellomedical.com/careers/locations/working-in-london/)
- [Working in Cambridge](https://www.costellomedical.com/careers/locations/working-in-cambridge/)
- [Joining Us From Academia](https://www.costellomedical.com/careers/working-at-costello-medical/joining-from-academia/)
- [Working in Boston](https://www.costellomedical.com/careers/locations/working-in-boston/)
- [Expression of Interest](https://www.costellomedical.com/force-for-good/pro-bono/expression-of-interest/)
- [Environment](https://www.costellomedical.com/force-for-good/environment/)
- [Outreach and Education](https://www.costellomedical.com/force-for-good/community/outreach-and-education/)
- [ISPOR Europe 2024](https://www.costellomedical.com/research/ispor-eu-event-2024/) - Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?HTA216
- [Register Your Interest](https://www.costellomedical.com/careers/register-your-interest/)
- [Access to Healthcare – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/access-to-healthcare/)
- [Cookie Policy](https://www.costellomedical.com/cookie-policy/)
- [ISPOR International 2024](https://www.costellomedical.com/research/ispor-us-event-2024/)
- [Rare Diseases – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/rare-diseases/)
- [Working in Bristol](https://www.costellomedical.com/careers/locations/working-in-bristol/)
- [Working in Shanghai](https://www.costellomedical.com/careers/locations/working-in-shanghai/)
- [Being a Better Business](https://www.costellomedical.com/being-a-better-business/)
- [Health Equity & Access – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/health-equity-and-access/)
- [Advancement of Statistical Methods to Overcome Evidence Gaps](https://www.costellomedical.com/research/ispor-eu-event-2023/report/advancement-of-statistical-methods-to-overcome-evidence-gaps/)
- [The Promise and Pitfalls of Generative AI for Health Economics](https://www.costellomedical.com/research/ispor-eu-event-2023/report/the-promise-and-pitfalls-of-generative-ai-for-health-economics/)
- [The EU Joint Clinical Assessment – Ready or Not, Here it Comes…](https://www.costellomedical.com/research/ispor-eu-event-2023/report/the-eu-joint-clinical-assessment/)
- [What is a Digital Health Technology? The PICOTS-ComTeC Framework Could Set the Standard](https://www.costellomedical.com/research/ispor-eu-event-2023/report/what-is-digital-health-technology/)
- [Environmental Responsibility and Patient Voice in Access and HEOR](https://www.costellomedical.com/research/ispor-eu-event-2023/report/environmental-responsibility-and-patient-voice-in-access-and-heor/)
- [The Ongoing Challenges of Immature Data](https://www.costellomedical.com/research/ispor-eu-event-2023/report/the-ongoing-challenges-of-immature-data/)
- [The Future Trajectory for RWE in European Healthcare Decision-Making](https://www.costellomedical.com/research/ispor-eu-event-2023/report/the-future-trajectory-for-rwe-in-european-healthcare-decision-making/)
- [Reimagining Rehabilitation in Brain Cancer](https://www.costellomedical.com/what-we-do/health-policy-public-affairs/health-policy/reimagining-rehabilitation-in-brain-cancer/)
- [Working in Manchester](https://www.costellomedical.com/careers/locations/working-in-manchester/)
- [ISPOR EU Event 2023 Enquiries](https://www.costellomedical.com/research/ispor-eu-event-2023/book-a-meeting/)
- [Reasonable Adjustments](https://www.costellomedical.com/reasonable-adjustments/)
- [Employee Stories](https://www.costellomedical.com/careers/working-at-costello-medical/employee-stories/)
- [RWE and Utilisation to Allow Faster Access to Markets](https://www.costellomedical.com/research/ispor-us-report-2022/rwe-and-utilisation-to-allow-faster-access-to-markets/)
- [Revisions to Medicaid Best Price Rule](https://www.costellomedical.com/research/ispor-us-report-2022/revisions-to-medicaid-best-price-rule/)
- [Patient Preference Elicitation and Incorporation into HTA/Access](https://www.costellomedical.com/research/ispor-us-report-2022/patient-preference-elicitation-and-incorporation-into-hta-access/)
- [Health Equity on the Agenda](https://www.costellomedical.com/research/ispor-us-report-2022/health-equity-on-the-agenda/)
- [Digital Health Technologies: Key Considerations for Reimbursement and Access](https://www.costellomedical.com/research/ispor-us-report-2022/digital-health-technologies-key-considerations-for-reimbursement-and-access/)
- [A Spotlight on Rare Diseases](https://www.costellomedical.com/research/ispor-us-report-2022/a-spotlight-on-rare-diseases/)
- [Working in Singapore](https://www.costellomedical.com/careers/locations/working-in-singapore/)
- [ISPOR US Report 2022](https://www.costellomedical.com/research/ispor-us-report-2022/)
- [East of England Global Health Conference](https://www.costellomedical.com/force-for-good/east-of-england-global-health-conference/)
- [ISPOR 2021 When Does “Access” Become “Established” in Rare Diseases?](https://www.costellomedical.com/research/when-does-access-become-established-in-rare-diseases/)
- [ISPOR 2021 Balancing Earlier Access and Data Immaturity](https://www.costellomedical.com/research/balancing-earlier-access-and-data-immaturity/)
- [ISPOR US Report 2023](https://www.costellomedical.com/research/ispor-us-report-2023/)
- [RWE in HTA and Regulatory Decisions](https://www.costellomedical.com/research/ispor-apac-2022/rwe-in-hta-and-regulatory-decisions/)
- [Paying for Value](https://www.costellomedical.com/research/ispor-apac-2022/paying-for-value/)
- [Incorporating Evidence for HTA Decision Making in Asia](https://www.costellomedical.com/research/ispor-apac-2022/incorporate-evidence-for-hta-decision-making-in-asia/)
- [ISPOR APAC 2022](https://www.costellomedical.com/research/ispor-apac-2022/)
- [Where Might HTA Be Heading?](https://www.costellomedical.com/research/ispor-eu-2022/where-might-hta-be-heading/)
- [Innovations in the Generation of High-Quality RWE](https://www.costellomedical.com/research/ispor-eu-2022/innovations-in-the-generation-of-high-quality-rwe/)
- [Hearing Patients Loud and Clear](https://www.costellomedical.com/research/ispor-eu-2022/hearing-patients-loud-and-clear/)
- [Collaboration Is Key – Real-World Evidence for Decision-Making](https://www.costellomedical.com/research/ispor-eu-2022/collaboration-is-key/)
- [Advancing Methodologies in Health Economic Modelling](https://www.costellomedical.com/research/ispor-eu-2022/advancing-methodologies-in-health-economic-modelling/)
- [ISPOR EU 2022](https://www.costellomedical.com/research/ispor-eu-2022/)
- [Next Steps for NICE in England – Westminster Health Forum 2023](https://www.costellomedical.com/research/next-steps-for-nice-in-england/)
- [Expanding Quantitative Methods of Value Assessment: Multi-Criteria Decision Analysis](https://www.costellomedical.com/research/ispor-us-report-2023/expanding-quantitative-methods-of-value-assessment/)
- [New Opportunities to Capture Wider Aspects of Value](https://www.costellomedical.com/research/ispor-us-report-2023/capturing-wider-aspects-of-value/)
- [Alternative Network Meta-Analysis Methods](https://www.costellomedical.com/research/ispor-us-report-2023/alternative-network-meta-analysis-methods/)
- [Spotlight on Real World Evidence](https://www.costellomedical.com/research/ispor-us-report-2023/spotlight-on-real-world-evidence/)
- [Unlocking New Insights with Artificial Intelligence](https://www.costellomedical.com/research/ispor-us-report-2023/unlocking-new-insights-with-artificial-intelligence/)
- [The IRA is Law – Now What?](https://www.costellomedical.com/research/ispor-us-report-2023/the-ira-is-law-now-what/)
- [Masterclasses](https://www.costellomedical.com/careers/working-at-costello-medical/masterclasses/)
- [Impact Mapping Skills Programme](https://www.costellomedical.com/force-for-good/pro-bono/impact-mapping-skills-programme/)
- [Rare Diseases Campaign](https://www.costellomedical.com/rare-diseases-campaign/)
- [Event Data Capture](https://www.costellomedical.com/event-form/)
- [Improving Mental Health – Call for Projects](https://www.costellomedical.com/force-for-good/pro-bono/improving-mental-health/)
- [Pro Bono Portfolio](https://www.costellomedical.com/force-for-good/pro-bono/pro-bono-portfolio/)
- [Portfolio](https://www.costellomedical.com/what-we-do/medical-communications/creative/portfolio/) - We work closely with our scientific teams to develop the design for a wide range of materials. View our portfolio page to see examples of our design work.

## Categories

- [Evidence Development](https://www.costellomedical.com/research/articles-publications/category/evidence-development/)
- [Statistics](https://www.costellomedical.com/research/articles-publications/category/statistics/)
- [Health Economics](https://www.costellomedical.com/research/articles-publications/category/health-economics/)
- [Health Technology Assessment](https://www.costellomedical.com/research/articles-publications/category/health-technology-assessment/)
- [Market Access](https://www.costellomedical.com/research/articles-publications/category/market-access/)
- [Medical Affairs](https://www.costellomedical.com/research/articles-publications/category/medical-affairs/)
- [Publications](https://www.costellomedical.com/research/articles-publications/category/publications/)
- [Creative](https://www.costellomedical.com/research/articles-publications/category/creative/)
- [Medical Devices](https://www.costellomedical.com/research/articles-publications/category/medical-devices/)
- [Rare Diseases](https://www.costellomedical.com/research/articles-publications/category/rare-diseases/)
- [MedTech](https://www.costellomedical.com/research/articles-publications/category/medtech/)
- [Real-World Evidence](https://www.costellomedical.com/research/articles-publications/category/real-world-evidence/)
- [Medical Communications](https://www.costellomedical.com/research/articles-publications/category/medical-communications/)
- [Literature Reviews](https://www.costellomedical.com/research/articles-publications/category/literature-reviews/)
- [Health Policy](https://www.costellomedical.com/research/articles-publications/category/health-policy/)
- [Patient Engagement](https://www.costellomedical.com/research/articles-publications/category/patient-engagement/)
- [Value & Access](https://www.costellomedical.com/research/articles-publications/category/value-access/)
- [Pro Bono](https://www.costellomedical.com/research/articles-publications/category/pro-bono/)
- [Technical Innovation](https://www.costellomedical.com/research/articles-publications/category/technical-innovation/)
- [Company](https://www.costellomedical.com/research/articles-publications/category/company/)

## Tags

- [ISPOR](https://www.costellomedical.com/research/articles-publications/tag/ispor/)
- [Glasgow](https://www.costellomedical.com/research/articles-publications/tag/glasgow/)
- [SLR](https://www.costellomedical.com/research/articles-publications/tag/slr/)
- [Systematic](https://www.costellomedical.com/research/articles-publications/tag/systematic/)
- [Literature](https://www.costellomedical.com/research/articles-publications/tag/literature/)
- [Disease](https://www.costellomedical.com/research/articles-publications/tag/disease/)
- [Methods](https://www.costellomedical.com/research/articles-publications/tag/methods/)
- [Review](https://www.costellomedical.com/research/articles-publications/tag/review/)
- [Burden](https://www.costellomedical.com/research/articles-publications/tag/burden/)
- [STA](https://www.costellomedical.com/research/articles-publications/tag/sta/)
- [MA](https://www.costellomedical.com/research/articles-publications/tag/ma/)
- [Value](https://www.costellomedical.com/research/articles-publications/tag/value/)
- [HTAi](https://www.costellomedical.com/research/articles-publications/tag/htai/)
- [Healthcare Access](https://www.costellomedical.com/research/articles-publications/tag/healthcare-access/)
- [Universal Health Coverage](https://www.costellomedical.com/research/articles-publications/tag/universal-health-coverage/)
- [Asia](https://www.costellomedical.com/research/articles-publications/tag/asia/)
- [Inequity](https://www.costellomedical.com/research/articles-publications/tag/inequity/)
- [China](https://www.costellomedical.com/research/articles-publications/tag/china/)
- [Taiwan](https://www.costellomedical.com/research/articles-publications/tag/taiwan/)
- [Korea](https://www.costellomedical.com/research/articles-publications/tag/korea/)
- [Thailand](https://www.costellomedical.com/research/articles-publications/tag/thailand/)
- [Boston](https://www.costellomedical.com/research/articles-publications/tag/boston/)
- [SME](https://www.costellomedical.com/research/articles-publications/tag/sme/)
- [Medical Technologies](https://www.costellomedical.com/research/articles-publications/tag/medical-technologies/)
- [MTEP](https://www.costellomedical.com/research/articles-publications/tag/mtep/)
- [NICE](https://www.costellomedical.com/research/articles-publications/tag/nice/)
- [PET-CT](https://www.costellomedical.com/research/articles-publications/tag/pet-ct/)
- [Adrenal Vein Sampling](https://www.costellomedical.com/research/articles-publications/tag/adrenal-vein-sampling/)
- [Hypertension](https://www.costellomedical.com/research/articles-publications/tag/hypertension/)
- [Cost-Effectiveness](https://www.costellomedical.com/research/articles-publications/tag/cost-effectiveness/)
- [Primary Aldosteronism](https://www.costellomedical.com/research/articles-publications/tag/primary-aldosteronism/)
- [Value Frameworks](https://www.costellomedical.com/research/articles-publications/tag/value-frameworks/)
- [Opinion](https://www.costellomedical.com/research/articles-publications/tag/opinion/)
- [Discussion](https://www.costellomedical.com/research/articles-publications/tag/discussion/)
- [ICER](https://www.costellomedical.com/research/articles-publications/tag/icer/)
- [ASCO](https://www.costellomedical.com/research/articles-publications/tag/asco/)
- [MSKCC](https://www.costellomedical.com/research/articles-publications/tag/mskcc/)
- [NCCN](https://www.costellomedical.com/research/articles-publications/tag/nccn/)
- [Report](https://www.costellomedical.com/research/articles-publications/tag/report/)
- [Conference](https://www.costellomedical.com/research/articles-publications/tag/conference/)
- [Medical Devices](https://www.costellomedical.com/research/articles-publications/tag/medical-devices/)
- [Oncology Modelling](https://www.costellomedical.com/research/articles-publications/tag/oncology-modelling/)
- [Orphan](https://www.costellomedical.com/research/articles-publications/tag/orphan/)
- [SMC](https://www.costellomedical.com/research/articles-publications/tag/smc/)
- [Managed Access Agreement](https://www.costellomedical.com/research/articles-publications/tag/managed-access-agreement/)
- [MAA](https://www.costellomedical.com/research/articles-publications/tag/maa/)
- [Model](https://www.costellomedical.com/research/articles-publications/tag/model/)
- [ERG](https://www.costellomedical.com/research/articles-publications/tag/erg/)
- [Evidence](https://www.costellomedical.com/research/articles-publications/tag/evidence/)
- [Markov](https://www.costellomedical.com/research/articles-publications/tag/markov/)
- [Cohort State-Transition](https://www.costellomedical.com/research/articles-publications/tag/cohort-state-transition/)
- [DICE](https://www.costellomedical.com/research/articles-publications/tag/dice/)
- [IPS](https://www.costellomedical.com/research/articles-publications/tag/ips/)
- [DAP](https://www.costellomedical.com/research/articles-publications/tag/dap/)
- [Diagnostics](https://www.costellomedical.com/research/articles-publications/tag/diagnostics/)
- [NHS](https://www.costellomedical.com/research/articles-publications/tag/nhs/)
- [Pricing](https://www.costellomedical.com/research/articles-publications/tag/pricing/)
- [Market Access](https://www.costellomedical.com/research/articles-publications/tag/market-access/)
- [Payer](https://www.costellomedical.com/research/articles-publications/tag/payer/)
- [Policy](https://www.costellomedical.com/research/articles-publications/tag/policy/)
- [Audit](https://www.costellomedical.com/research/articles-publications/tag/audit/)
- [PAS](https://www.costellomedical.com/research/articles-publications/tag/pas/)
- [Patient Access](https://www.costellomedical.com/research/articles-publications/tag/patient-access/)
- [Technology Appraisal](https://www.costellomedical.com/research/articles-publications/tag/technology-appraisal/)
- [Discount](https://www.costellomedical.com/research/articles-publications/tag/discount/)
- [NMA](https://www.costellomedical.com/research/articles-publications/tag/nma/)
- [Meta-Analysis](https://www.costellomedical.com/research/articles-publications/tag/meta-analysis/)
- [ITC](https://www.costellomedical.com/research/articles-publications/tag/itc/)
- [Singapore](https://www.costellomedical.com/research/articles-publications/tag/singapore/)
- [ACE](https://www.costellomedical.com/research/articles-publications/tag/ace/)
- [Agency](https://www.costellomedical.com/research/articles-publications/tag/agency/)
- [Care](https://www.costellomedical.com/research/articles-publications/tag/care/)
- [Effectiveness](https://www.costellomedical.com/research/articles-publications/tag/effectiveness/)
- [Ministry of Health](https://www.costellomedical.com/research/articles-publications/tag/ministry-of-health/)
- [MAF](https://www.costellomedical.com/research/articles-publications/tag/maf/)
- [DAC](https://www.costellomedical.com/research/articles-publications/tag/dac/)
- [Australia](https://www.costellomedical.com/research/articles-publications/tag/australia/)
- [PBAC](https://www.costellomedical.com/research/articles-publications/tag/pbac/)
- [Pharmaceutical Benefits Advisory Committee](https://www.costellomedical.com/research/articles-publications/tag/pharmaceutical-benefits-advisory-committee/)
- [Consumer Comments](https://www.costellomedical.com/research/articles-publications/tag/consumer-comments/)
- [Utility](https://www.costellomedical.com/research/articles-publications/tag/utility/)
- [Health State](https://www.costellomedical.com/research/articles-publications/tag/health-state/)
- [HSUV](https://www.costellomedical.com/research/articles-publications/tag/hsuv/)
- [EQ-5D](https://www.costellomedical.com/research/articles-publications/tag/eq-5d/)
- [Oncology](https://www.costellomedical.com/research/articles-publications/tag/oncology/)
- [MAIC](https://www.costellomedical.com/research/articles-publications/tag/maic/)
- [STC](https://www.costellomedical.com/research/articles-publications/tag/stc/)
- [Indirect Comparison](https://www.costellomedical.com/research/articles-publications/tag/indirect-comparison/)
- [MedTech](https://www.costellomedical.com/research/articles-publications/tag/medtech/)
- [Surgery](https://www.costellomedical.com/research/articles-publications/tag/surgery/)
- [Rare Disease](https://www.costellomedical.com/research/articles-publications/tag/rare-disease/)
- [Real-World Evidence](https://www.costellomedical.com/research/articles-publications/tag/real-world-evidence/)
- [RWE](https://www.costellomedical.com/research/articles-publications/tag/rwe/)
- [Liverpool](https://www.costellomedical.com/research/articles-publications/tag/liverpool/)
- [Value Proposition](https://www.costellomedical.com/research/articles-publications/tag/value-proposition/)
- [Guidance](https://www.costellomedical.com/research/articles-publications/tag/guidance/)
- [FTA](https://www.costellomedical.com/research/articles-publications/tag/fta/)
- [HST](https://www.costellomedical.com/research/articles-publications/tag/hst/)
- [Consultation](https://www.costellomedical.com/research/articles-publications/tag/consultation/)
- [Rome](https://www.costellomedical.com/research/articles-publications/tag/rome/)
- [Patient Involvement](https://www.costellomedical.com/research/articles-publications/tag/patient-involvement/)
- [Big Data](https://www.costellomedical.com/research/articles-publications/tag/big-data/)
- [Telemedicine](https://www.costellomedical.com/research/articles-publications/tag/telemedicine/)
- [ISMPP](https://www.costellomedical.com/research/articles-publications/tag/ismpp/)
- [London](https://www.costellomedical.com/research/articles-publications/tag/london/)
- [Augmented Reality](https://www.costellomedical.com/research/articles-publications/tag/augmented-reality/)
- [AR](https://www.costellomedical.com/research/articles-publications/tag/ar/)
- [Congress](https://www.costellomedical.com/research/articles-publications/tag/congress/)
- [App](https://www.costellomedical.com/research/articles-publications/tag/app/)
- [Zappar](https://www.costellomedical.com/research/articles-publications/tag/zappar/)
- [Blippar](https://www.costellomedical.com/research/articles-publications/tag/blippar/)
- [Aurasma](https://www.costellomedical.com/research/articles-publications/tag/aurasma/)
- [Scientific](https://www.costellomedical.com/research/articles-publications/tag/scientific/)
- [Intern](https://www.costellomedical.com/research/articles-publications/tag/intern/)
- [Professional](https://www.costellomedical.com/research/articles-publications/tag/professional/)
- [Medical](https://www.costellomedical.com/research/articles-publications/tag/medical/)
- [Communications](https://www.costellomedical.com/research/articles-publications/tag/communications/)
- [Recruitment](https://www.costellomedical.com/research/articles-publications/tag/recruitment/)
- [Research](https://www.costellomedical.com/research/articles-publications/tag/research/)
- [Oral](https://www.costellomedical.com/research/articles-publications/tag/oral/)
- [Abstract](https://www.costellomedical.com/research/articles-publications/tag/abstract/)
- [Poster](https://www.costellomedical.com/research/articles-publications/tag/poster/)
- [Sponsorship](https://www.costellomedical.com/research/articles-publications/tag/sponsorship/)
- [RCT](https://www.costellomedical.com/research/articles-publications/tag/rct/)
- [EULAR](https://www.costellomedical.com/research/articles-publications/tag/eular/)
- [Journal](https://www.costellomedical.com/research/articles-publications/tag/journal/)
- [Lay](https://www.costellomedical.com/research/articles-publications/tag/lay/)
- [Summary](https://www.costellomedical.com/research/articles-publications/tag/summary/)
- [Editorial](https://www.costellomedical.com/research/articles-publications/tag/editorial/)
- [Publishing](https://www.costellomedical.com/research/articles-publications/tag/publishing/)
- [Data](https://www.costellomedical.com/research/articles-publications/tag/data/)
- [Transparency](https://www.costellomedical.com/research/articles-publications/tag/transparency/)
- [Patient](https://www.costellomedical.com/research/articles-publications/tag/patient/)
- [AMWA](https://www.costellomedical.com/research/articles-publications/tag/amwa/)
- [EMWA](https://www.costellomedical.com/research/articles-publications/tag/emwa/)
- [Washington](https://www.costellomedical.com/research/articles-publications/tag/washington/)
- [Digital](https://www.costellomedical.com/research/articles-publications/tag/digital/)
- [Social Media](https://www.costellomedical.com/research/articles-publications/tag/social-media/)
- [Planning](https://www.costellomedical.com/research/articles-publications/tag/planning/)
- [Involvement](https://www.costellomedical.com/research/articles-publications/tag/involvement/)
- [Open Access](https://www.costellomedical.com/research/articles-publications/tag/open-access/)
- [Metrics](https://www.costellomedical.com/research/articles-publications/tag/metrics/)
- [Rare Diseases](https://www.costellomedical.com/research/articles-publications/tag/rare-diseases/)
- [HEOR](https://www.costellomedical.com/research/articles-publications/tag/heor/)
- [Accessibility](https://www.costellomedical.com/research/articles-publications/tag/accessibility/)
- [Paediatric](https://www.costellomedical.com/research/articles-publications/tag/paediatric/)
- [Orphanet](https://www.costellomedical.com/research/articles-publications/tag/orphanet/)
- [Manuscript](https://www.costellomedical.com/research/articles-publications/tag/manuscript/)
- [Citation](https://www.costellomedical.com/research/articles-publications/tag/citation/)
- [Buzzword](https://www.costellomedical.com/research/articles-publications/tag/buzzword/)
- [Reporting](https://www.costellomedical.com/research/articles-publications/tag/reporting/)
- [Adherence](https://www.costellomedical.com/research/articles-publications/tag/adherence/)
- [Guidelines](https://www.costellomedical.com/research/articles-publications/tag/guidelines/)
- [CONSORT](https://www.costellomedical.com/research/articles-publications/tag/consort/)
- [PRISMA](https://www.costellomedical.com/research/articles-publications/tag/prisma/)
- [STROBE](https://www.costellomedical.com/research/articles-publications/tag/strobe/)
- [Delphi](https://www.costellomedical.com/research/articles-publications/tag/delphi/)
- [AGREE](https://www.costellomedical.com/research/articles-publications/tag/agree/)
- [Consensus](https://www.costellomedical.com/research/articles-publications/tag/consensus/)
- [Findacure](https://www.costellomedical.com/research/articles-publications/tag/findacure/)
- [Drug Repurposing](https://www.costellomedical.com/research/articles-publications/tag/drug-repurposing/)
- [Reimbursement](https://www.costellomedical.com/research/articles-publications/tag/reimbursement/)
- [SMi](https://www.costellomedical.com/research/articles-publications/tag/smi/)
- [Collaboration](https://www.costellomedical.com/research/articles-publications/tag/collaboration/)
- [Access](https://www.costellomedical.com/research/articles-publications/tag/access/)
- [Devices](https://www.costellomedical.com/research/articles-publications/tag/devices/)
- [Innovation](https://www.costellomedical.com/research/articles-publications/tag/innovation/)
- [Vienna](https://www.costellomedical.com/research/articles-publications/tag/vienna/)
- [European Reference Networks](https://www.costellomedical.com/research/articles-publications/tag/european-reference-networks/)
- [ERN](https://www.costellomedical.com/research/articles-publications/tag/ern/)
- [EMA](https://www.costellomedical.com/research/articles-publications/tag/ema/)
- [PRIME](https://www.costellomedical.com/research/articles-publications/tag/prime/)
- [BeNeLuxA](https://www.costellomedical.com/research/articles-publications/tag/beneluxa/)
- [Medical Affairs](https://www.costellomedical.com/research/articles-publications/tag/medical-affairs/)
- [Wet AMD](https://www.costellomedical.com/research/articles-publications/tag/wet-amd/)
- [Macular Degeneration](https://www.costellomedical.com/research/articles-publications/tag/macular-degeneration/)
- [HTA](https://www.costellomedical.com/research/articles-publications/tag/hta/)
- [Visual Acuity](https://www.costellomedical.com/research/articles-publications/tag/visual-acuity/)
- [Quality of Life](https://www.costellomedical.com/research/articles-publications/tag/quality-of-life/)
- [Multiple Sclerosis](https://www.costellomedical.com/research/articles-publications/tag/multiple-sclerosis/)
- [RRMS](https://www.costellomedical.com/research/articles-publications/tag/rrms/)
- [Discrete Event Simulation](https://www.costellomedical.com/research/articles-publications/tag/discrete-event-simulation/)
- [DES](https://www.costellomedical.com/research/articles-publications/tag/des/)
- [Alemtuzumab](https://www.costellomedical.com/research/articles-publications/tag/alemtuzumab/)
- [QALY](https://www.costellomedical.com/research/articles-publications/tag/qaly/)
- [Epilepsy](https://www.costellomedical.com/research/articles-publications/tag/epilepsy/)
- [Anti-Epileptic Drugs](https://www.costellomedical.com/research/articles-publications/tag/anti-epileptic-drugs/)
- [Long-Term Retention](https://www.costellomedical.com/research/articles-publications/tag/long-term-retention/)
- [Literature Review](https://www.costellomedical.com/research/articles-publications/tag/literature-review/)
- [Assisted Reproductive Technology](https://www.costellomedical.com/research/articles-publications/tag/assisted-reproductive-technology/)
- [Luteal Phase Support](https://www.costellomedical.com/research/articles-publications/tag/luteal-phase-support/)
- [Vaginal Progesterone](https://www.costellomedical.com/research/articles-publications/tag/vaginal-progesterone/)
- [Systematic Literature Review](https://www.costellomedical.com/research/articles-publications/tag/systematic-literature-review/)
- [Hyperkalaemia](https://www.costellomedical.com/research/articles-publications/tag/hyperkalaemia/)
- [Disease Management](https://www.costellomedical.com/research/articles-publications/tag/disease-management/)
- [Hepatitis C](https://www.costellomedical.com/research/articles-publications/tag/hepatitis-c/)
- [Liver](https://www.costellomedical.com/research/articles-publications/tag/liver/)
- [Vasa Praevia](https://www.costellomedical.com/research/articles-publications/tag/vasa-praevia/)
- [Rapid Review](https://www.costellomedical.com/research/articles-publications/tag/rapid-review/)
- [Screening](https://www.costellomedical.com/research/articles-publications/tag/screening/)
- [UK](https://www.costellomedical.com/research/articles-publications/tag/uk/)
- [mHealth](https://www.costellomedical.com/research/articles-publications/tag/mhealth/)
- [NICE HAB](https://www.costellomedical.com/research/articles-publications/tag/nice-hab/)
- [SHTG IMTO](https://www.costellomedical.com/research/articles-publications/tag/shtg-imto/)
- [Early Arthritis](https://www.costellomedical.com/research/articles-publications/tag/early-arthritis/)
- [EAS](https://www.costellomedical.com/research/articles-publications/tag/eas/)
- [Patient Satisfaction](https://www.costellomedical.com/research/articles-publications/tag/patient-satisfaction/)
- [Survival Modelling](https://www.costellomedical.com/research/articles-publications/tag/survival-modelling/)
- [Immuno-Oncology](https://www.costellomedical.com/research/articles-publications/tag/immuno-oncology/)
- [MIBs](https://www.costellomedical.com/research/articles-publications/tag/mibs/)
- [Real-World Data](https://www.costellomedical.com/research/articles-publications/tag/real-world-data/)
- [Medical Writing](https://www.costellomedical.com/research/articles-publications/tag/medical-writing/)
- [Publications](https://www.costellomedical.com/research/articles-publications/tag/publications/)
- [White Paper](https://www.costellomedical.com/research/articles-publications/tag/white-paper/)
- [Ataxia](https://www.costellomedical.com/research/articles-publications/tag/ataxia/)
- [Value Assessment](https://www.costellomedical.com/research/articles-publications/tag/value-assessment/)
- [USA](https://www.costellomedical.com/research/articles-publications/tag/usa/)
- [Scientific Communication](https://www.costellomedical.com/research/articles-publications/tag/scientific-communication/)
- [Health Economics](https://www.costellomedical.com/research/articles-publications/tag/health-economics/)
- [Budget Impact](https://www.costellomedical.com/research/articles-publications/tag/budget-impact/)
- [Vaccination](https://www.costellomedical.com/research/articles-publications/tag/vaccination/)
- [Medicaid](https://www.costellomedical.com/research/articles-publications/tag/medicaid/)
- [Affordable Care Act](https://www.costellomedical.com/research/articles-publications/tag/affordable-care-act/)
- [Opioid Replacement Therapy](https://www.costellomedical.com/research/articles-publications/tag/opioid-replacement-therapy/)
- [Opioid Crisis](https://www.costellomedical.com/research/articles-publications/tag/opioid-crisis/)
- [Framework Synthesis](https://www.costellomedical.com/research/articles-publications/tag/framework-synthesis/)
- [Neuroendocrine Tumour](https://www.costellomedical.com/research/articles-publications/tag/neuroendocrine-tumour/)
- [Differential Diagnosis](https://www.costellomedical.com/research/articles-publications/tag/differential-diagnosis/)
- [Carcinoid Syndrome](https://www.costellomedical.com/research/articles-publications/tag/carcinoid-syndrome/)
- [Systematic Review](https://www.costellomedical.com/research/articles-publications/tag/systematic-review/)
- [Health Policy](https://www.costellomedical.com/research/articles-publications/tag/health-policy/)
- [Payment Reform](https://www.costellomedical.com/research/articles-publications/tag/payment-reform/)
- [Cost-Control](https://www.costellomedical.com/research/articles-publications/tag/cost-control/)
- [Institute for Clinical and Economic Review](https://www.costellomedical.com/research/articles-publications/tag/institute-for-clinical-and-economic-review/)
- [US](https://www.costellomedical.com/research/articles-publications/tag/us/)
- [infectious diseases](https://www.costellomedical.com/research/articles-publications/tag/infectious-diseases/)
- [cost-effectiveness analysis](https://www.costellomedical.com/research/articles-publications/tag/cost-effectiveness-analysis/)
- [Switzerland](https://www.costellomedical.com/research/articles-publications/tag/switzerland/)
- [network meta-analysis](https://www.costellomedical.com/research/articles-publications/tag/network-meta-analysis/)
- [type 1 diabetes](https://www.costellomedical.com/research/articles-publications/tag/type-1-diabetes/)
- [hierarchical network meta-analysis](https://www.costellomedical.com/research/articles-publications/tag/hierarchical-network-meta-analysis/)
- [familial hypercholesterolemia](https://www.costellomedical.com/research/articles-publications/tag/familial-hypercholesterolemia/)
- [cross-sectional study](https://www.costellomedical.com/research/articles-publications/tag/cross-sectional-study/)
- [patient survey](https://www.costellomedical.com/research/articles-publications/tag/patient-survey/)
- [mixed effects modelling](https://www.costellomedical.com/research/articles-publications/tag/mixed-effects-modelling/)
- [Asia-Pacific](https://www.costellomedical.com/research/articles-publications/tag/asia-pacific/)
- [Utility Values](https://www.costellomedical.com/research/articles-publications/tag/utility-values/)
- [Clinical Code Sets](https://www.costellomedical.com/research/articles-publications/tag/clinical-code-sets/)
- [EVPPI](https://www.costellomedical.com/research/articles-publications/tag/evppi/)
- [CADTH](https://www.costellomedical.com/research/articles-publications/tag/cadth/)
- [Scientific Advice](https://www.costellomedical.com/research/articles-publications/tag/scientific-advice/)
- [Nivolumab](https://www.costellomedical.com/research/articles-publications/tag/nivolumab/)
- [Gene Therapies](https://www.costellomedical.com/research/articles-publications/tag/gene-therapies/)
- [Capacity](https://www.costellomedical.com/research/articles-publications/tag/capacity/)
- [Delayed Access](https://www.costellomedical.com/research/articles-publications/tag/delayed-access/)
- [Copenhagen](https://www.costellomedical.com/research/articles-publications/tag/copenhagen/)
- [2019](https://www.costellomedical.com/research/articles-publications/tag/2019/)
- [EU](https://www.costellomedical.com/research/articles-publications/tag/eu/)
- [2020](https://www.costellomedical.com/research/articles-publications/tag/2020/)
- [Patients](https://www.costellomedical.com/research/articles-publications/tag/patients/)
- [Congresses](https://www.costellomedical.com/research/articles-publications/tag/congresses/)
- [2021](https://www.costellomedical.com/research/articles-publications/tag/2021/)
- [FDA](https://www.costellomedical.com/research/articles-publications/tag/fda/)
- [Cell and Gene Therapy](https://www.costellomedical.com/research/articles-publications/tag/cell-and-gene-therapy/)
- [NSCLC](https://www.costellomedical.com/research/articles-publications/tag/nsclc/)
- [2022](https://www.costellomedical.com/research/articles-publications/tag/2022/)
- [2023](https://www.costellomedical.com/research/articles-publications/tag/2023/)
- [Health Economics and Statistics](https://www.costellomedical.com/research/articles-publications/tag/health-economics-and-statistics/)
- [Evidence Development](https://www.costellomedical.com/research/articles-publications/tag/evidence-development/)
- [Literature Reviews and Synthesis](https://www.costellomedical.com/research/articles-publications/tag/literature-reviews-and-synthesis/)
- [2024](https://www.costellomedical.com/research/articles-publications/tag/2024/)
- [Medical Communications](https://www.costellomedical.com/research/articles-publications/tag/medical-communications/)
- [Health Technology Assessment](https://www.costellomedical.com/research/articles-publications/tag/health-technology-assessment/)
- [Pro Bono](https://www.costellomedical.com/research/articles-publications/tag/pro-bono/)
- [Heath Technology Assessment](https://www.costellomedical.com/research/articles-publications/tag/heath-technology-assessment/)
- [Literature Reviews & Synthesis](https://www.costellomedical.com/research/articles-publications/tag/literature-reviews-synthesis/)
- [Value & Access](https://www.costellomedical.com/research/articles-publications/tag/value-access/)
- [JCA](https://www.costellomedical.com/research/articles-publications/tag/jca/)
- [Opinion Piece](https://www.costellomedical.com/research/articles-publications/tag/opinion-piece/)
- [Dossier Template](https://www.costellomedical.com/research/articles-publications/tag/dossier-template/)
- [ABHI](https://www.costellomedical.com/research/articles-publications/tag/abhi/)
- [AI](https://www.costellomedical.com/research/articles-publications/tag/ai/)
- [PICOS](https://www.costellomedical.com/research/articles-publications/tag/picos/)
- [Vaccines](https://www.costellomedical.com/research/articles-publications/tag/vaccines/)
- [CPRD](https://www.costellomedical.com/research/articles-publications/tag/cprd/)
- [Delphi Panels](https://www.costellomedical.com/research/articles-publications/tag/delphi-panels/)
- [Ophthalmology](https://www.costellomedical.com/research/articles-publications/tag/ophthalmology/)
- [Environmental Impact](https://www.costellomedical.com/research/articles-publications/tag/environmental-impact/)
- [Scotland](https://www.costellomedical.com/research/articles-publications/tag/scotland/)
- [Literature Reviews](https://www.costellomedical.com/research/articles-publications/tag/literature-reviews/)
- [United Kingdom](https://www.costellomedical.com/research/articles-publications/tag/united-kingdom/)
- [HCRU](https://www.costellomedical.com/research/articles-publications/tag/hcru/)
- [patient engagement](https://www.costellomedical.com/research/articles-publications/tag/patient-engagement/)
- [Statistics](https://www.costellomedical.com/research/articles-publications/tag/statistics/)
- [Observational Evidence](https://www.costellomedical.com/research/articles-publications/tag/observational-evidence/)
- [APAC](https://www.costellomedical.com/research/articles-publications/tag/apac/)
- [North America](https://www.costellomedical.com/research/articles-publications/tag/north-america/)
- [Artificial Intelligence](https://www.costellomedical.com/research/articles-publications/tag/artificial-intelligence/)
- [Oral Presentation](https://www.costellomedical.com/research/articles-publications/tag/oral-presentation/)
- [Article](https://www.costellomedical.com/research/articles-publications/tag/article/)
- [Creative](https://www.costellomedical.com/research/articles-publications/tag/creative/)
- [2025](https://www.costellomedical.com/research/articles-publications/tag/2025/)
- [Sage](https://www.costellomedical.com/research/articles-publications/tag/sage/)
- [Targeted Literature Review](https://www.costellomedical.com/research/articles-publications/tag/targeted-literature-review/)
- [Evidence-Based Research](https://www.costellomedical.com/research/articles-publications/tag/evidence-based-research/)
- [Framework](https://www.costellomedical.com/research/articles-publications/tag/framework/)
- [Value Dossier](https://www.costellomedical.com/research/articles-publications/tag/value-dossier/)
- [Value Dossier Development​](https://www.costellomedical.com/research/articles-publications/tag/value-dossier-development/)
- [network](https://www.costellomedical.com/research/articles-publications/tag/network/)
- [Minimally Important Differences](https://www.costellomedical.com/research/articles-publications/tag/minimally-important-differences/)
- [qualitative research studies](https://www.costellomedical.com/research/articles-publications/tag/qualitative-research-studies/)
- [RSV Vaccine](https://www.costellomedical.com/research/articles-publications/tag/rsv-vaccine/)
- [Respiratory syncytial virus](https://www.costellomedical.com/research/articles-publications/tag/respiratory-syncytial-virus/)
- [Infectious disease](https://www.costellomedical.com/research/articles-publications/tag/infectious-disease/)
- [Vaccine Rollout](https://www.costellomedical.com/research/articles-publications/tag/vaccine-rollout/)
- [Joint Clinical Assessment](https://www.costellomedical.com/research/articles-publications/tag/joint-clinical-assessment/)
- [advanced therapy medicinal products](https://www.costellomedical.com/research/articles-publications/tag/advanced-therapy-medicinal-products/)
- [Technical Innovation](https://www.costellomedical.com/research/articles-publications/tag/technical-innovation/)
- [Patient-Centric Strategies](https://www.costellomedical.com/research/articles-publications/tag/patient-centric-strategies/)
- [Value Dossiers](https://www.costellomedical.com/research/articles-publications/tag/value-dossiers/)
- [GenAI](https://www.costellomedical.com/research/articles-publications/tag/genai/)
- [pharmaceutical](https://www.costellomedical.com/research/articles-publications/tag/pharmaceutical/)
- [Health Inequalities](https://www.costellomedical.com/research/articles-publications/tag/health-inequalities/)
- [Digital Design](https://www.costellomedical.com/research/articles-publications/tag/digital-design/)
- [UX Design](https://www.costellomedical.com/research/articles-publications/tag/ux-design/)
- [UX](https://www.costellomedical.com/research/articles-publications/tag/ux/)
- [UI](https://www.costellomedical.com/research/articles-publications/tag/ui/)
- [UI Design](https://www.costellomedical.com/research/articles-publications/tag/ui-design/)
- [Healthcare](https://www.costellomedical.com/research/articles-publications/tag/healthcare/)
- [Motion Design](https://www.costellomedical.com/research/articles-publications/tag/motion-design/)
- [Video](https://www.costellomedical.com/research/articles-publications/tag/video/)
- [Public Engagement](https://www.costellomedical.com/research/articles-publications/tag/public-engagement/)
- [Pharma](https://www.costellomedical.com/research/articles-publications/tag/pharma/)
- [Medical Education](https://www.costellomedical.com/research/articles-publications/tag/medical-education/)
- [HST Programme](https://www.costellomedical.com/research/articles-publications/tag/hst-programme/)
- [COVID-19](https://www.costellomedical.com/research/articles-publications/tag/covid-19/)
- [AMCP 2023](https://www.costellomedical.com/research/articles-publications/tag/amcp-2023/)
- [Prescription Drugs](https://www.costellomedical.com/research/articles-publications/tag/prescription-drugs/)
- [The Inflation Reduction Act](https://www.costellomedical.com/research/articles-publications/tag/the-inflation-reduction-act/)
- [AMCP](https://www.costellomedical.com/research/articles-publications/tag/amcp/)
- [AMCP 2022](https://www.costellomedical.com/research/articles-publications/tag/amcp-2022/)
- [ISMPP EU 2025](https://www.costellomedical.com/research/articles-publications/tag/ismpp-eu-2025/)
- [ISPOR 2025](https://www.costellomedical.com/research/articles-publications/tag/ispor-2025/)
- [Value and Access](https://www.costellomedical.com/research/articles-publications/tag/value-and-access/)
- [MedComms](https://www.costellomedical.com/research/articles-publications/tag/medcomms/)
- [Data Generation](https://www.costellomedical.com/research/articles-publications/tag/data-generation/)
- [US Healthcare Policy](https://www.costellomedical.com/research/articles-publications/tag/us-healthcare-policy/)
- [ISPOR 2024](https://www.costellomedical.com/research/articles-publications/tag/ispor-2024/)
- [Graphic Design](https://www.costellomedical.com/research/articles-publications/tag/graphic-design/)
- [Data Transportability](https://www.costellomedical.com/research/articles-publications/tag/data-transportability/)
- [Statistical Methods](https://www.costellomedical.com/research/articles-publications/tag/statistical-methods/)
- [Innovations](https://www.costellomedical.com/research/articles-publications/tag/innovations/)
- [ISPOR International 2024](https://www.costellomedical.com/research/articles-publications/tag/ispor-international-2024/)
- [IRA](https://www.costellomedical.com/research/articles-publications/tag/ira/)
- [Drug Price](https://www.costellomedical.com/research/articles-publications/tag/drug-price/)
- [Whole health](https://www.costellomedical.com/research/articles-publications/tag/whole-health/)
- [Wrong Pocket Problem](https://www.costellomedical.com/research/articles-publications/tag/wrong-pocket-problem/)
- [Digital health](https://www.costellomedical.com/research/articles-publications/tag/digital-health/)
- [Data Source Landscaping](https://www.costellomedical.com/research/articles-publications/tag/data-source-landscaping/)
- [ISMPP 2025](https://www.costellomedical.com/research/articles-publications/tag/ismpp-2025/)
- [Value Assessment Frameworks](https://www.costellomedical.com/research/articles-publications/tag/value-assessment-frameworks/)
- [Digital Age](https://www.costellomedical.com/research/articles-publications/tag/digital-age/)
- [digital health technologies](https://www.costellomedical.com/research/articles-publications/tag/digital-health-technologies/)
- [Systematic Reviews](https://www.costellomedical.com/research/articles-publications/tag/systematic-reviews/)
- [Economic Literature Reviews](https://www.costellomedical.com/research/articles-publications/tag/economic-literature-reviews/)
- [Drummond Checklist](https://www.costellomedical.com/research/articles-publications/tag/drummond-checklist/)
- [ISMPP 2026](https://www.costellomedical.com/research/articles-publications/tag/ismpp-2026/)
- [SXSW](https://www.costellomedical.com/research/articles-publications/tag/sxsw/)

## Service Area

- [Health Policy](https://www.costellomedical.com/?casestudy_service=health-policy)
- [Health Economics](https://www.costellomedical.com/?casestudy_service=health-economics)
- [Statistics](https://www.costellomedical.com/?casestudy_service=statistics)
- [HTA](https://www.costellomedical.com/?casestudy_service=hta)
- [Literature Reviews](https://www.costellomedical.com/?casestudy_service=literature-reviews)
- [Real-World Evidence](https://www.costellomedical.com/?casestudy_service=real-world-evidence)
- [Market Access](https://www.costellomedical.com/?casestudy_service=market-access)
- [Rare Diseases](https://www.costellomedical.com/?casestudy_service=rare-diseases)
- [Creative](https://www.costellomedical.com/?casestudy_service=creative)
- [Marketing](https://www.costellomedical.com/?casestudy_service=marketing)
- [Medical Communications](https://www.costellomedical.com/?casestudy_service=medical-communication)
- [Evidence Development](https://www.costellomedical.com/?casestudy_service=evidence-development)
- [Value & Access](https://www.costellomedical.com/?casestudy_service=value-and-access)
- [Patient Engagement](https://www.costellomedical.com/?casestudy_service=patient-engagement)

## Category

- [Graphic Design](https://www.costellomedical.com/?portfolio_type=graphic-design)
- [Pro Bono](https://www.costellomedical.com/?portfolio_type=pro-bono)
- [Motion Design](https://www.costellomedical.com/?portfolio_type=motion-design)
- [Digital Design](https://www.costellomedical.com/?portfolio_type=digital-design)

## Tags

- [Branding](https://www.costellomedical.com/?portfolio_tags=branding)
- [Graphic Design](https://www.costellomedical.com/?portfolio_tags=graphic-design)
- [Illustration](https://www.costellomedical.com/?portfolio_tags=illustration)
- [Print Design](https://www.costellomedical.com/?portfolio_tags=print-design)
- [Design](https://www.costellomedical.com/?portfolio_tags=design)
- [Digital Design](https://www.costellomedical.com/?portfolio_tags=digital-design)
- [Mental Health](https://www.costellomedical.com/?portfolio_tags=mental-health)
- [Marketing](https://www.costellomedical.com/?portfolio_tags=marketing)
- [Data Visualisation](https://www.costellomedical.com/?portfolio_tags=data-visualisation)
- [Video](https://www.costellomedical.com/?portfolio_tags=video)
- [Digital](https://www.costellomedical.com/?portfolio_tags=digital)
- [Infographic](https://www.costellomedical.com/?portfolio_tags=infographic)
- [e-learning](https://www.costellomedical.com/?portfolio_tags=e-learning)
- [Literature Review](https://www.costellomedical.com/?portfolio_tags=literature-review)
- [Economic Modelling](https://www.costellomedical.com/?portfolio_tags=economic-modelling)
- [Cancer](https://www.costellomedical.com/?portfolio_tags=cancer)
- [Research](https://www.costellomedical.com/?portfolio_tags=research)
- [Antibiotic](https://www.costellomedical.com/?portfolio_tags=antibiotic)
- [Literature](https://www.costellomedical.com/?portfolio_tags=literature)
- [Engagement](https://www.costellomedical.com/?portfolio_tags=engagement)
- [Rare Disease](https://www.costellomedical.com/?portfolio_tags=rare-disease)
- [Findacure](https://www.costellomedical.com/?portfolio_tags=findacure)
- [Publication](https://www.costellomedical.com/?portfolio_tags=publication)
- [Stakeholders](https://www.costellomedical.com/?portfolio_tags=stakeholders)
- [Web Development](https://www.costellomedical.com/?portfolio_tags=web-development)
- [Pro Bono](https://www.costellomedical.com/?portfolio_tags=pro-bono)
- [Myeloma](https://www.costellomedical.com/?portfolio_tags=myeloma)
- [Health Economics](https://www.costellomedical.com/?portfolio_tags=health-economics)
- [Design & Layout](https://www.costellomedical.com/?portfolio_tags=design-layout)
- [Animation](https://www.costellomedical.com/?portfolio_tags=animation)
- [UI Design](https://www.costellomedical.com/?portfolio_tags=ui-design)
- [UX Design](https://www.costellomedical.com/?portfolio_tags=ux-design)
- [SEO](https://www.costellomedical.com/?portfolio_tags=seo)
- [Interactive](https://www.costellomedical.com/?portfolio_tags=interactive)
- [Footage](https://www.costellomedical.com/?portfolio_tags=footage)
- [Audio](https://www.costellomedical.com/?portfolio_tags=audio)
- [Patient-Friendly Language](https://www.costellomedical.com/?portfolio_tags=patient-friendly-language)
- [Medical Education](https://www.costellomedical.com/?portfolio_tags=medical-education)
- [Advocacy](https://www.costellomedical.com/?portfolio_tags=advocacy)
- [Access](https://www.costellomedical.com/?portfolio_tags=access)
- [Roundtable](https://www.costellomedical.com/?portfolio_tags=roundtable)
- [Motion Design](https://www.costellomedical.com/?portfolio_tags=motion-design)
- [Education](https://www.costellomedical.com/?portfolio_tags=education)
- [Patient Experience](https://www.costellomedical.com/?portfolio_tags=patient-experience)
- [Focus Groups](https://www.costellomedical.com/?portfolio_tags=focus-groups)
- [Training](https://www.costellomedical.com/?portfolio_tags=training)
- [Event Management](https://www.costellomedical.com/?portfolio_tags=event-management)
- [Logistics](https://www.costellomedical.com/?portfolio_tags=logistics)
- [Lay-friendly](https://www.costellomedical.com/?portfolio_tags=lay-friendly)
- [Patient Education](https://www.costellomedical.com/?portfolio_tags=patient-education)
- [Review](https://www.costellomedical.com/?portfolio_tags=review)
- [Modelling](https://www.costellomedical.com/?portfolio_tags=modelling)
- [Poster](https://www.costellomedical.com/?portfolio_tags=poster)
- [Social Value](https://www.costellomedical.com/?portfolio_tags=social-value)
- [Funding](https://www.costellomedical.com/?portfolio_tags=funding)
- [Communication](https://www.costellomedical.com/?portfolio_tags=communication)
- [Stakeholder Engagement](https://www.costellomedical.com/?portfolio_tags=stakeholder-engagement)
- [Interviews](https://www.costellomedical.com/?portfolio_tags=interviews)
- [Validation](https://www.costellomedical.com/?portfolio_tags=validation)
- [RWE](https://www.costellomedical.com/?portfolio_tags=rwe)
- [RWD](https://www.costellomedical.com/?portfolio_tags=rwd)
- [Social Media](https://www.costellomedical.com/?portfolio_tags=social-media)
- [Value](https://www.costellomedical.com/?portfolio_tags=value)
- [Impact](https://www.costellomedical.com/?portfolio_tags=impact)
- [UX/UI Design](https://www.costellomedical.com/?portfolio_tags=ux-ui-design)
- [Patient Engagement](https://www.costellomedical.com/?portfolio_tags=patient-engagement)
- [Lay Materials](https://www.costellomedical.com/?portfolio_tags=lay-materials)
- [Accessibility](https://www.costellomedical.com/?portfolio_tags=accessibility)
- [Hybrid](https://www.costellomedical.com/?portfolio_tags=hybrid)
- [Report Development](https://www.costellomedical.com/?portfolio_tags=report-development)
- [Virtual](https://www.costellomedical.com/?portfolio_tags=virtual)
- [Patient Materials](https://www.costellomedical.com/?portfolio_tags=patient-materials)
- [Policy](https://www.costellomedical.com/?portfolio_tags=policy)
- [Patient-Centred Care](https://www.costellomedical.com/?portfolio_tags=patient-centred-care)
- [Sexual Health](https://www.costellomedical.com/?portfolio_tags=sexual-health)
- [Global Health](https://www.costellomedical.com/?portfolio_tags=global-health)
- [Digital Technology](https://www.costellomedical.com/?portfolio_tags=digital-technology)
- [Strategy](https://www.costellomedical.com/?portfolio_tags=strategy)
- [Endometriosis](https://www.costellomedical.com/?portfolio_tags=endometriosis)
- [Tool Refinement](https://www.costellomedical.com/?portfolio_tags=tool-refinement)
- [Manuscript](https://www.costellomedical.com/?portfolio_tags=manuscript)
- [Research Strategy](https://www.costellomedical.com/?portfolio_tags=research-strategy)
- [Medical Communication](https://www.costellomedical.com/?portfolio_tags=medical-communication)
- [Journal Digest](https://www.costellomedical.com/?portfolio_tags=journal-digest)
- [Adolescents](https://www.costellomedical.com/?portfolio_tags=adolescents)
- [Young Adults](https://www.costellomedical.com/?portfolio_tags=young-adults)
- [Omnichannel](https://www.costellomedical.com/?portfolio_tags=omnichannel)
- [Community](https://www.costellomedical.com/?portfolio_tags=community)
- [Innovation](https://www.costellomedical.com/?portfolio_tags=innovation)

## Type

- [Poster](https://www.costellomedical.com/?article_type=poster)
- [Report](https://www.costellomedical.com/?article_type=report)
- [Oral Presentation](https://www.costellomedical.com/?article_type=oral-presentation)
- [Article](https://www.costellomedical.com/?article_type=article)
- [Abstract](https://www.costellomedical.com/?article_type=abstract)
- [News](https://www.costellomedical.com/?article_type=news)
- [Webinar](https://www.costellomedical.com/?article_type=webinar)

## Event

- [ISPOR](https://www.costellomedical.com/?article_event=ispor)
- [ISMPP](https://www.costellomedical.com/?article_event=ismpp)
- [ABHI](https://www.costellomedical.com/?article_event=abhi)
- [NICE](https://www.costellomedical.com/?article_event=nice)
- [AMCP](https://www.costellomedical.com/?article_event=amcp)
- [HTAi](https://www.costellomedical.com/?article_event=htai)
- [ECRD](https://www.costellomedical.com/?article_event=ecrd)

## Year

- [2024](https://www.costellomedical.com/?article_year=2024)
- [2023](https://www.costellomedical.com/?article_year=2023)
- [2021](https://www.costellomedical.com/?article_year=2021)
- [2022](https://www.costellomedical.com/?article_year=2022)
- [2025](https://www.costellomedical.com/?article_year=2025)
- [2020](https://www.costellomedical.com/?article_year=2020)
- [2019](https://www.costellomedical.com/?article_year=2019)
- [2018](https://www.costellomedical.com/?article_year=2018)
- [2017](https://www.costellomedical.com/?article_year=2017)
- [2016](https://www.costellomedical.com/?article_year=2016)
- [2015](https://www.costellomedical.com/?article_year=2015)
- [2026](https://www.costellomedical.com/?article_year=2026)

## Job Type

- [Scientific Vacancies](https://www.costellomedical.com/?job_type=scientific-vacancies)
- [Economic and Statistic Vacancies](https://www.costellomedical.com/?job_type=economic-and-statistic-vacancies)
- [Internship and Placement Vacancies](https://www.costellomedical.com/?job_type=internship-and-placement-vacancies)
- [Design Vacancies](https://www.costellomedical.com/?job_type=design-vacancies)
- [Operations Vacancies](https://www.costellomedical.com/?job_type=operations-vacancies)

## Location

- [Cambridge, UK](https://www.costellomedical.com/?location=cambridge)
- [London, UK](https://www.costellomedical.com/?location=london)
- [Singapore](https://www.costellomedical.com/?location=singapore)
- [Manchester, UK](https://www.costellomedical.com/?location=manchester)
- [Shanghai](https://www.costellomedical.com/?location=shanghai)
- [Boston, MA](https://www.costellomedical.com/?location=boston)